Search

Your search keyword '"Campagnolo M"' showing total 230 results
Start Over Author "Campagnolo M"
230 results on '"Campagnolo M"'

1. Unclassified clinical presentations of chronic inflammatory demyelinating polyradiculoneuropathy

Author

Doneddu, P, Akyil, H, Manganelli, F, Briani, C, Cocito, D, Benedetti, L, Mazzeo, A, Fazio, R, Filosto, M, Cosentino, G, Di Stefano, V, Antonini, G, Marfia, G, Inghilleri, M, Siciliano, G, Clerici, A, Carpo, M, Schenone, A, Luigetti, M, Lauria, G, Mata, S, Rosso, T, Minicuci, G, Lucchetta, M, Cavaletti, G, Liberatore, G, Spina, E, Campagnolo, M, Peci, E, Germano, F, Gentile, L, Strano, C, Cotti Piccinelli, S, Vegezzi, E, Leonardi, L, Mataluni, G, Ceccanti, M, Schirinzi, E, Romozzi, M, Nobile-Orazio, E, Doneddu P. E., Akyil H., Manganelli F., Briani C., Cocito D., Benedetti L., Mazzeo A., Fazio R., Filosto M., Cosentino G., Di Stefano V., Antonini G., Marfia G. A., Inghilleri M., Siciliano G., Clerici A. M., Carpo M., Schenone A., Luigetti M., Lauria G., Mata S., Rosso T., Minicuci G. M., Lucchetta M., Cavaletti G., Liberatore G., Spina E., Campagnolo M., Peci E., Germano F., Gentile L., Strano C., Cotti Piccinelli S., Vegezzi E., Leonardi L., Mataluni G., Ceccanti M., Schirinzi E., Romozzi M., Nobile-Orazio E., Doneddu, P, Akyil, H, Manganelli, F, Briani, C, Cocito, D, Benedetti, L, Mazzeo, A, Fazio, R, Filosto, M, Cosentino, G, Di Stefano, V, Antonini, G, Marfia, G, Inghilleri, M, Siciliano, G, Clerici, A, Carpo, M, Schenone, A, Luigetti, M, Lauria, G, Mata, S, Rosso, T, Minicuci, G, Lucchetta, M, Cavaletti, G, Liberatore, G, Spina, E, Campagnolo, M, Peci, E, Germano, F, Gentile, L, Strano, C, Cotti Piccinelli, S, Vegezzi, E, Leonardi, L, Mataluni, G, Ceccanti, M, Schirinzi, E, Romozzi, M, Nobile-Orazio, E, Doneddu P. E., Akyil H., Manganelli F., Briani C., Cocito D., Benedetti L., Mazzeo A., Fazio R., Filosto M., Cosentino G., Di Stefano V., Antonini G., Marfia G. A., Inghilleri M., Siciliano G., Clerici A. M., Carpo M., Schenone A., Luigetti M., Lauria G., Mata S., Rosso T., Minicuci G. M., Lucchetta M., Cavaletti G., Liberatore G., Spina E., Campagnolo M., Peci E., Germano F., Gentile L., Strano C., Cotti Piccinelli S., Vegezzi E., Leonardi L., Mataluni G., Ceccanti M., Schirinzi E., Romozzi M., and Nobile-Orazio E.

Abstract

Background To assess the ability of the 2021 European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) clinical criteria for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) to include within their classification the whole spectrum of clinical heterogeneity of the disease and to define the clinical characteristics of the unclassifiable clinical forms. Methods The 2021 EAN/PNS clinical criteria for CIDP were applied to 329 patients fulfilling the electrodiagnostic (and in some cases also the supportive) criteria for the diagnosis of CIDP. Clinical characteristics were reviewed for each patient not strictly fulfilling the clinical criteria ('unclassifiable'). Results At study inclusion, 124 (37.5%) patients had an unclassifiable clinical presentation, including 110 (89%) with a typical CIDP-like clinical phenotype in whom some segments of the four limbs were unaffected by weakness ('incomplete typical CIDP'), 10 (8%) with a mild distal, symmetric, sensory or sensorimotor polyneuropathy confined to the lower limbs with cranial nerve involvement ('cranial nerve predominant CIDP') and 4 (1%) with a symmetric sensorimotor polyneuropathy limited to the proximal and distal areas of the lower limbs ('paraparetic CIDP'). Eighty-one (65%) patients maintained an unclassifiable presentation during the entire disease follow-up while 13 patients progressed to typical CIDP. Patients with the unclassifiable clinical forms compared with patients with typical CIDP had a milder form of CIDP, while there was no difference in the distribution patterns of demyelination. Conclusions A proportion of patients with CIDP do not strictly fulfil the 2021 EAN/PNS clinical criteria for diagnosis. These unclassifiable clinical phenotypes may pose diagnostic challenges and thus deserve more attention in clinical practice and research.

Published
2023

3. The PROVENT-C19 registry: A study protocol for international multicenter SIAARTI registry on the use of prone positioning in mechanically ventilated patients with COVID-19 ARDS

Author

De Rosa, S, Sella, N, Rezoagli, E, Lorenzoni, G, Gregori, D, Bellani, G, Foti, G, Pettenuzzo, T, Baratto, F, Fullin, G, Papaccio, F, Peta, M, Poole, D, Toffoletto, F, Maggiore, S, Navales, P, Navalesi, P, Tiberio, I, Pasin, L, Godi, I, Serra, E, Zarantonello, F, Andreatta, G, Boscolo, A, Persona, P, Cattin, L, Forin, E, Boni, E, Golino, G, Danzi, V, Vetrugno, L, Cornacchia, N, Donadello, K, Gottin, L, Polati, E, Campagnolo, M, Linassi, F, Panciera, G, Garofalo, E, Bruni, A, Carlon, R, Pipitone, M, Candosin, A, Badii, F, Role, S, Girardis, M, Busani, S, Gamberini, E, Tartivita, C, Gamberini, L, Cortegiani, A, Frisella, S, Ippolito, M, Salvo, F, Greco, M, Cecconi, M, Aceto, R, Langer, T, Repishti, M, Zeduri, A, Ottolina, D, Fossali, T, Colombo, R, Predonzani, N, Ferluga, M, Blasi, S, Zardin, M, Vergine, S, Luccarelli, G, Tritapepe, L, Francesconi, A, Pagani, M, Mojoli, F, Orlando, A, Mongodi, S, Bitondo, M, Johnathan, M, Maugeri, J, Bellissima, A, Guzzardella, A, Vallecoccia, M, Spadaro, S, Cricca, V, Andriolo, E, Bianchin, A, Alampi, D, Rocco, M, Anchisi, S, Tenaglia, T, Nicoletti, R, Antonini, B, Zanaty, M, Mogahed, M, Ali, A, Emara, M, Abdullah, E, Awad, A, Abdel-Maboud, M, Hussein, A, Mosleh, A, Ahmed, M, Aziz, M, Elsayed, A, Aldhalia, A, Elkhatid, A, Abodina, A, Khalleefah, A, Shalabi, L, Shamed, H, Bakeer, H, Hawad, A, Abuzaid, T, Alqandouz, R, Saliga, A, Haddud, A, Kredan, A, Shaban, M, Salama, A, Altabit, A, Alflite, A, Hashim, H, Kadhim, Q, Abd-Alreda, A, Al-Juifari, M, Al-Gburi, S, Akram, A, Laila, A, Bakri, A, Abdelmageed, A, Binnawara, M, Mohamed, M, Esaadi, H, Othman, E, Said, A, Alarabi, R, Alameen, H, Albouishi, N, Babaa, K, Salih, R, Elbakheet, D, Abuelyamen, A, Perez-Torres, D, Mattson, J, Al-Sadawi, M, Elseidy, S, De Rosa S., Sella N., Rezoagli E., Lorenzoni G., Gregori D., Bellani G., Foti G., Pettenuzzo T., Baratto F., Fullin G., Papaccio F., Peta M., Poole D., Toffoletto F., Maggiore S. M., Navales P., Navalesi P., Tiberio I., Pasin L., Godi I., Serra E., Zarantonello F., Andreatta G., Boscolo A., Persona P., Cattin L., Forin E., Boni E., Golino G., Danzi V., Vetrugno L., Cornacchia N., Donadello K., Gottin L., Polati E., Campagnolo M., Linassi F., Panciera G., Garofalo E., Bruni A., Carlon R., Pipitone M., Candosin A., Badii F., Role S. D., Girardis M., Busani S., Gamberini E., Tartivita C. N., Gamberini L., Cortegiani A., Frisella S., Ippolito M., Salvo F., Greco M., Cecconi M., Aceto R., Langer T., Repishti M., Zeduri A., Ottolina D., Fossali T., Colombo R., Predonzani N., Ferluga M., Blasi S. D., Zardin M., Vergine S., Luccarelli G., Tritapepe L., Francesconi A. G., Pagani M., Mojoli F., Orlando A., Mongodi S., Bitondo M., Johnathan M., Maugeri J., Bellissima A., Guzzardella A., Vallecoccia M. S., Spadaro S., Cricca V., Andriolo E., Bianchin A., Alampi D., Rocco M., Anchisi S., Tenaglia T., Nicoletti R., Antonini B., Zanaty M., Mogahed M., Ali A., Emara M., Abdullah E., Awad A. K., Abdel-Maboud M., Hussein A. M., Hussein A. A. R. M., Mosleh A. A., Ahmed M. G., Aziz M. G., Elsayed A., Aldhalia A., Elkhatid A., Abodina A. M., Khalleefah A., Shalabi L. E., Shamed H., Bakeer H. B., Hawad A., Abuzaid T., Alqandouz R. A. S., Saliga A. A., Haddud A., Kredan A. A., Shaban M. S., Salama A. A., Altabit A. E. R. M., Alflite A. O. S., Hashim H. T., Kadhim Q. M., Abd-Alreda A. H., Al-Juifari M. A., Al-Gburi S. M., Akram A., Laila A., Bakri A., Abdelmageed A., Binnawara M., Mohamed M., Esaadi H., Othman E., Said A., Alarabi R., Alameen H., Albouishi N., Babaa K. A., Salih R., Elbakheet D. E., Abuelyamen A., Perez-Torres D., Mattson J., Al-Sadawi M., Elseidy S., De Rosa, S, Sella, N, Rezoagli, E, Lorenzoni, G, Gregori, D, Bellani, G, Foti, G, Pettenuzzo, T, Baratto, F, Fullin, G, Papaccio, F, Peta, M, Poole, D, Toffoletto, F, Maggiore, S, Navales, P, Navalesi, P, Tiberio, I, Pasin, L, Godi, I, Serra, E, Zarantonello, F, Andreatta, G, Boscolo, A, Persona, P, Cattin, L, Forin, E, Boni, E, Golino, G, Danzi, V, Vetrugno, L, Cornacchia, N, Donadello, K, Gottin, L, Polati, E, Campagnolo, M, Linassi, F, Panciera, G, Garofalo, E, Bruni, A, Carlon, R, Pipitone, M, Candosin, A, Badii, F, Role, S, Girardis, M, Busani, S, Gamberini, E, Tartivita, C, Gamberini, L, Cortegiani, A, Frisella, S, Ippolito, M, Salvo, F, Greco, M, Cecconi, M, Aceto, R, Langer, T, Repishti, M, Zeduri, A, Ottolina, D, Fossali, T, Colombo, R, Predonzani, N, Ferluga, M, Blasi, S, Zardin, M, Vergine, S, Luccarelli, G, Tritapepe, L, Francesconi, A, Pagani, M, Mojoli, F, Orlando, A, Mongodi, S, Bitondo, M, Johnathan, M, Maugeri, J, Bellissima, A, Guzzardella, A, Vallecoccia, M, Spadaro, S, Cricca, V, Andriolo, E, Bianchin, A, Alampi, D, Rocco, M, Anchisi, S, Tenaglia, T, Nicoletti, R, Antonini, B, Zanaty, M, Mogahed, M, Ali, A, Emara, M, Abdullah, E, Awad, A, Abdel-Maboud, M, Hussein, A, Mosleh, A, Ahmed, M, Aziz, M, Elsayed, A, Aldhalia, A, Elkhatid, A, Abodina, A, Khalleefah, A, Shalabi, L, Shamed, H, Bakeer, H, Hawad, A, Abuzaid, T, Alqandouz, R, Saliga, A, Haddud, A, Kredan, A, Shaban, M, Salama, A, Altabit, A, Alflite, A, Hashim, H, Kadhim, Q, Abd-Alreda, A, Al-Juifari, M, Al-Gburi, S, Akram, A, Laila, A, Bakri, A, Abdelmageed, A, Binnawara, M, Mohamed, M, Esaadi, H, Othman, E, Said, A, Alarabi, R, Alameen, H, Albouishi, N, Babaa, K, Salih, R, Elbakheet, D, Abuelyamen, A, Perez-Torres, D, Mattson, J, Al-Sadawi, M, Elseidy, S, De Rosa S., Sella N., Rezoagli E., Lorenzoni G., Gregori D., Bellani G., Foti G., Pettenuzzo T., Baratto F., Fullin G., Papaccio F., Peta M., Poole D., Toffoletto F., Maggiore S. M., Navales P., Navalesi P., Tiberio I., Pasin L., Godi I., Serra E., Zarantonello F., Andreatta G., Boscolo A., Persona P., Cattin L., Forin E., Boni E., Golino G., Danzi V., Vetrugno L., Cornacchia N., Donadello K., Gottin L., Polati E., Campagnolo M., Linassi F., Panciera G., Garofalo E., Bruni A., Carlon R., Pipitone M., Candosin A., Badii F., Role S. D., Girardis M., Busani S., Gamberini E., Tartivita C. N., Gamberini L., Cortegiani A., Frisella S., Ippolito M., Salvo F., Greco M., Cecconi M., Aceto R., Langer T., Repishti M., Zeduri A., Ottolina D., Fossali T., Colombo R., Predonzani N., Ferluga M., Blasi S. D., Zardin M., Vergine S., Luccarelli G., Tritapepe L., Francesconi A. G., Pagani M., Mojoli F., Orlando A., Mongodi S., Bitondo M., Johnathan M., Maugeri J., Bellissima A., Guzzardella A., Vallecoccia M. S., Spadaro S., Cricca V., Andriolo E., Bianchin A., Alampi D., Rocco M., Anchisi S., Tenaglia T., Nicoletti R., Antonini B., Zanaty M., Mogahed M., Ali A., Emara M., Abdullah E., Awad A. K., Abdel-Maboud M., Hussein A. M., Hussein A. A. R. M., Mosleh A. A., Ahmed M. G., Aziz M. G., Elsayed A., Aldhalia A., Elkhatid A., Abodina A. M., Khalleefah A., Shalabi L. E., Shamed H., Bakeer H. B., Hawad A., Abuzaid T., Alqandouz R. A. S., Saliga A. A., Haddud A., Kredan A. A., Shaban M. S., Salama A. A., Altabit A. E. R. M., Alflite A. O. S., Hashim H. T., Kadhim Q. M., Abd-Alreda A. H., Al-Juifari M. A., Al-Gburi S. M., Akram A., Laila A., Bakri A., Abdelmageed A., Binnawara M., Mohamed M., Esaadi H., Othman E., Said A., Alarabi R., Alameen H., Albouishi N., Babaa K. A., Salih R., Elbakheet D. E., Abuelyamen A., Perez-Torres D., Mattson J., Al-Sadawi M., and Elseidy S.

Abstract

Background The worldwide use of prone position (PP) for invasively ventilated patients with COVID-19 is progressively increasing from the first pandemic wave in everyday clinical practice. Among the suggested treatments for the management of ARDS patients, PP was recommended in the Surviving Sepsis Campaign COVID-19 guidelines as an adjuvant therapy for improving ventilation. In patients with severe classical ARDS, some authors reported that early application of prolonged PP sessions significantly decreases 28-day and 90-day mortality. Methods and analysis Since January 2021, the COVID19 Veneto ICU Network research group has developed and implemented nationally and internationally the "PROVENT-C19 Registry", endorsed by the Italian Society of Anesthesia Analgesia Resuscitation and Intensive Care. . .'(SIAARTI). The PROVENT-C19 Registry wishes to describe 1. The real clinical practice on the use of PP in COVID-19 patients during the pandemic at a National and International level; and 2. Potential baseline and clinical characteristics that identify subpopulations of invasively ventilated patients with COVID-19 that may improve daily from PP therapy. This web-based registry will provide relevant information on how the database research tools may improve our daily clinical practice. Conclusions This multicenter, prospective registry is the first to identify and characterize the role of PP on clinical outcome in COVID-19 patients. In recent years, data emerging from large registries have been increasingly used to provide real-world evidence on the effectiveness, quality, and safety of a clinical intervention. Indeed observation-based registries could be effective tools aimed at identifying specific clusters of patients within a large study population with widely heterogeneous clinical characteristics. Copyright

Published
2022

4. Risk of disease relapse, safety and tolerability of SARS-CoV-2 vaccination in patients with chronic inflammatory neuropathies

Author

Doneddu, P. E., Briani, C., Cocito, D., Manganelli, F., Fabrizi, G. M., Matà, S., Mazzeo, A., Fazio, R., Benedetti, L., Luigetti, M., Inghilleri, M., Ruiu, E., Siciliano, G., Cosentino, G., Marfia, G. A., Carpo, M., Filosto, M., Antonini, G., Notturno, F., Sotgiu, S., Cucurachi, L., Dell'Aquila, C., Bianchi, E., Rosso, T., Giordano, A., Fernandes, M., Campagnolo, M., Peci, E., Spina, E., Tagliapietra, M., Sperti, M., Gentile, L., Strano, C., Germano, F., Romozzi, M., Moret, F., Zarbo, I. R., Viola, D. V., Vegezzi, E., Mataluni, G., Cotti-Piccinelli, S., Leonardi, L., Carta, A., and Nobile-Orazio, E.

Subjects
COVID-19, SARS-CoV-2, chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, vaccination, Settore MED/26
Published
2023

5. Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20)

Author

Kieffer, Jacobien M., Postma, Tjeerd J., van de Poll-Franse, Lonneke, Mols, Floortje, Heimans, Jan J., Cavaletti, Guido, Aaronson, Neil K., Cavaletti, G., Cornblath, D. R., Merkies, I. S. J., Postma, T. J., Valsecchi, M. G., Galimberti, S., Rossi, E., Cavaletti, G., Frigeni, B., Lanzani, F., Mattavelli, L., Piatti, M. L., Alberti, P., Binda, D., Bidoli, P., Cazzaniga, M., Cortinovis, D., Bruna, J., Velasco, R., Argyriou, A. A., Kalofonos, H. P., Psimaras, D., Ricard, D., Pace, A., Galiè, E., Briani, C., Lucchetta, M., Campagnolo, M., Torre, C. Dalla, Faber, C. G., Merkies, I. S. J., Vanhoutte, E. K., Bakkers, M., Brouwer, B., Boogerd, M., Lalisang, R. I., Boogerd, W., Brandsma, D., Koeppen, S., Hense, J., Grant, R., Storey, D., Kerrigan, S., Schenone, A., Reni, L., Piras, B., Fabbri, S., Pessino, A., Padua, L., Granata, G., Leandri, M., Ghignotti, I., Plasmati, R., Pastorelli, F., Postma, T. J., Heimans, J. J., Eurelings, M., Meijer, R. J., Grisold, W., Pozza, E. Lindeck, Mazzeo, A., Toscano, A., Russo, M., Tomasello, C., Altavilla, G., Prado, M. Penas, Gonzalez, C. Dominguez, Dorsey, S. G., and In Collaboration with the CI-PeriNomS Group

Published
2017
Full Text
View/download PDF

6. Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin

Author

Cavaletti, G., Cornblath, D.R., Merkies, I.S.J., Postma, T.J., Valsecchi, M.G, Galimberti, S., Rossi, E., Frigeni, B., Lanzani, F., Mattavelli, L., Piatti, M.L., Alberti, P., Binda, D., Bidoli, P., Cazzaniga, M., Cortinovis, D., Bruna, J., Velasco, R., Argyriou, A.A., Kalofonos, H.P., Psimaras, D., Ricard, D., Pace, A., Galiè, E., Briani, C., Lucchetta, M., Campagnolo, M., Dalla Torre, C., Faber, C.G., Vanhoutte, E.K., Bakkers, M., Brouwer, B., Lalisang, R.I., Boogerd, W., Brandsma, D., Koeppen, S., Hense, J., Grant, R., Storey, D., Kerrigan, S., Schenone, A., Reni, L., Piras, B., Fabbri, S., Padua, L., Granata, G., Leandri, M., Ghignotti, I., Plasmati, R., Pastorelli, F., Heimans, J.J., Eurelings, M., Meijer, R.J., Grisold, W., Lindeck Pozza, E., Mazzeo, A., Toscano, A., Tomasello, C., Altavilla, G., Penas Prado, M., Dominguez Gonzalez, C., Dorsey, S.G., Brell, J.M., and Valsecchi, M.G.

Published
2014
Full Text
View/download PDF

8. A 3‐year interval is too short for re‐screening women testing negative for human papillomavirus: a population‐based cohort study

Author

Zorzi, M, Frayle, H, Rizzi, M, Fedato, C, Rugge, M, Penon, MG, Bertazzo, A, Callegaro, S, Campagnolo, M, Ortu, F, Del Mistro, A, Baracco, Susanna, Baboci, Lorena, Amadori, Alberto, Montaguti, Adriana, Turrin, Anna, Farruggio, Angelo, Cocco, Patrizia, Tumaini, Lucio, Gerace, Pierfrancesco, Borgato, Loretta, Maso, Renata, Bo, Patrizio, Mari, Lucia, Franzoi, Roberto, and Ferro, Antonio

Published
2017
Full Text
View/download PDF

9. The PROVENT-C19 registry: A study protocol for international multicenter SIAARTI registry on the use of prone positioning in mechanically ventilated patients with COVID-19 ARDS

Author

De Rosa, S., Sella, N., Rezoagli, E., Lorenzoni, G., Gregori, D., Bellani, G., Foti, G., Pettenuzzo, T., Baratto, F., Fullin, G., Papaccio, F., Peta, M., Poole, D., Toffoletto, F., Maggiore, S. M., Navales, P., Navalesi, P., Tiberio, I., Pasin, L., Godi, I., Serra, E., Zarantonello, F., Andreatta, G., Boscolo, A., Persona, P., Cattin, L., Forin, E., Boni, E., Golino, G., Danzi, V., Vetrugno, L., Cornacchia, N., Donadello, K., Gottin, L., Polati, E., Campagnolo, M., Linassi, F., Panciera, G., Garofalo, E., Bruni, A., Carlon, R., Pipitone, M., Candosin, A., Badii, F., Role, S. D., Girardis, M., Busani, S., Gamberini, E., Tartivita, C. N., Gamberini, L., Cortegiani, A., Frisella, S., Ippolito, M., Salvo, F., Greco, M., Cecconi, M., Aceto, R., Langer, T., Repishti, M., Zeduri, A., Ottolina, D., Fossali, T., Colombo, R., Predonzani, N., Ferluga, M., Blasi, S. D., Zardin, M., Vergine, S., Luccarelli, G., Tritapepe, L., Francesconi, A. G., Pagani, M., Mojoli, F., Orlando, A., Mongodi, S., Bitondo, M., Johnathan, M., Maugeri, J., Bellissima, A., Guzzardella, A., Vallecoccia, M. S., Spadaro, S., Cricca, V., Andriolo, E., Bianchin, A., Alampi, D., Rocco, M., Anchisi, S., Tenaglia, T., Nicoletti, R., Antonini, B., Zanaty, M., Mogahed, M., Ali, A., Emara, M., Abdullah, E., Awad, A. K., Abdel-Maboud, M., Hussein, A. M., Hussein, A. A. R. M., Mosleh, A. A., Ahmed, M. G., Aziz, M. G., Elsayed, A., Aldhalia, A., Elkhatid, A., Abodina, A. M., Khalleefah, A., Shalabi, L. E., Shamed, H., Bakeer, H. B., Hawad, A., Abuzaid, T., Alqandouz, R. A. S., Saliga, A. A., Haddud, A., Kredan, A. A., Shaban, M. S., Salama, A. A., Altabit, A. E. R. M., Alflite, A. O. S., Hashim, H. T., Kadhim, Q. M., Abd-Alreda, A. H., Al-Juifari, M. A., Al-Gburi, S. M., Akram, A., Laila, A., Bakri, A., Abdelmageed, A., Binnawara, M., Mohamed, M., Esaadi, H., Othman, E., Said, A., Alarabi, R., Alameen, H., Albouishi, N., Babaa, K. A., Salih, R., Elbakheet, D. E., Abuelyamen, A., Perez-Torres, D., Mattson, J., Al-Sadawi, M., Elseidy, S., De Rosa, Silvia, Sella, Nicolò, Rezoagli, Emanuele, Lorenzoni, Giulia, Gregori, Dario, Bellani, Giacomo, Foti, Giuseppe, Pettenuzzo, Tommaso, Baratto, Fabio, Fullin, Giorgio, Papaccio, Francesco, Peta, Mario, Poole, Daniele, Toffoletto, Fabio, Maggiore, Salvatore Maurizio, Navalesi, Paolo, SIAARTI Study group, Cortegiani, Andrea, Frisella, Sara, and Ippolito, Mariachiara

Subjects
Multidisciplinary, prone position, respiratory failure, COVID-19
Abstract

Background The worldwide use of prone position (PP) for invasively ventilated patients with COVID-19 is progressively increasing from the first pandemic wave in everyday clinical practice. Among the suggested treatments for the management of ARDS patients, PP was recommended in the Surviving Sepsis Campaign COVID-19 guidelines as an adjuvant therapy for improving ventilation. In patients with severe classical ARDS, some authors reported that early application of prolonged PP sessions significantly decreases 28-day and 90-day mortality. Methods and analysis Since January 2021, the COVID19 Veneto ICU Network research group has developed and implemented nationally and internationally the “PROVENT-C19 Registry”, endorsed by the Italian Society of Anesthesia Analgesia Resuscitation and Intensive Care…’(SIAARTI). The PROVENT-C19 Registry wishes to describe 1. The real clinical practice on the use of PP in COVID-19 patients during the pandemic at a National and International level; and 2. Potential baseline and clinical characteristics that identify subpopulations of invasively ventilated patients with COVID-19 that may improve daily from PP therapy. This web-based registry will provide relevant information on how the database research tools may improve our daily clinical practice. Conclusions This multicenter, prospective registry is the first to identify and characterize the role of PP on clinical outcome in COVID-19 patients. In recent years, data emerging from large registries have been increasingly used to provide real-world evidence on the effectiveness, quality, and safety of a clinical intervention. Indeed observation-based registries could be effective tools aimed at identifying specific clusters of patients within a large study population with widely heterogeneous clinical characteristics. Trial registration The registry was registered (ClinicalTrial.Gov Trials Register NCT04905875) on May 28,2021.

Published
2022

11. Clinician-rated measures for distal symmetrical axonal polyneuropathy: ACTTION systematic review

Author

Gewandter, J, Gibbons, C, Campagnolo, M, Lee, J, Chaudari, J, Ward, N, Burke, L, Cavaletti, G, Herrmann, D, Mcarthur, J, Russell, J, Smith, A, Smith, S, Turk, D, Dworkin, R, Freeman, R, Gewandter J. S., Gibbons C. H., Campagnolo M., Lee J., Chaudari J., Ward N., Burke L., Cavaletti G., Herrmann D. N., McArthur J. C., Russell J. W., Smith A. G., Smith S. M., Turk D. C., Dworkin R. H., Freeman R., Gewandter, J, Gibbons, C, Campagnolo, M, Lee, J, Chaudari, J, Ward, N, Burke, L, Cavaletti, G, Herrmann, D, Mcarthur, J, Russell, J, Smith, A, Smith, S, Turk, D, Dworkin, R, Freeman, R, Gewandter J. S., Gibbons C. H., Campagnolo M., Lee J., Chaudari J., Ward N., Burke L., Cavaletti G., Herrmann D. N., McArthur J. C., Russell J. W., Smith A. G., Smith S. M., Turk D. C., Dworkin R. H., and Freeman R.

Abstract

Distal symmetrical axonal polyneuropathy (DSP) is due to injury to peripheral sensory, motor, and autonomic nerve fibers, resulting in distal predominant sensory loss, pain, and gait instability. DSP occurs as a complication of multiple medical conditions including diabetes or HIV, or following exposure to various toxins such as chemotherapy. It affects at least 10% of the United States population. Few treatments for DSP are approved by regulatory agencies. Reliable and responsive outcome measures are integral to developing new DSP treatments. Multiple clinician-rated measures that incorporate neuropathy signs exist, however, it is not clear which of these measures performs best for various DSP phenotypes. This systematic review summarizes the content of 18 published measures of DSP identified using PubMed and from personal archives of the authors. The relative percentage of scoring dedicated to motor, reflex, large and small fiber sensory, and autonomic domains varied considerably among measures. The most common neurologic examination items included in the scales were (1) vibration perception (n = 18, 100%), (2) reflexes (n = 16, 89%), (3) pinprick perception (n = 14, 78%), (4) muscle strength (n = 11, 61%), (5) touch-pressure perception (n = 9, 50%), and (6) joint position perception (n = 8, 44%). This review can be used to inform decisions regarding which of the available clinician-rated sign outcome measures would be most appropriate for use in a particular DSP population, based on the domains most affected by that neuropathy or on the domains most likely to be affected by a particular experimental therapy.

Published
2019

12. Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity

Author

Cavaletti, G., Cornblath, D. R., Merkies, I. S. J., Postma, T. J., Rossi, E., Alberti, Paola, Bruna, J., Argyriou, A. A., Briani, C., Velasco, Riccardo, Kalofonos, H. P., Psimaras, D., Ricard, D., Pace, A., Faber, C. G., Lalisang, R. I., Brandsma, D., Koeppen, S., Kerrigan, S., Schenone, A., Grisold, W., Mazzeo, A., Padua, L., Dorsey, S. G., Penas-Prado, M., Valsecchi, M. G., Frigeni, B., Lanzani, F., Mattavelli, L., Piatti, M. L., Binda, D., Bidoli, P., Cazzaniga, M., Cortinovis, D., Galie, E., Campagnolo, M., Salvalaggio, A., Ruiz, M., Vanhoutte, E. K., Boogerd, W., Hense, J., Grant, R., Storey, D., Reni, L., Demichelis, C., Pessino, A., Granata, G., Leandri, Martina, Ghigliotti, I., Plasmati, R., Pastorelli, Federica, Heimans, J. J., Eurelings, M., Meijer, R. J., Pozza, E. L., Toscano, A., Gentile, L., Santarpia, M., Gonzalez, C. D., Klinische Neurowetenschappen, MUMC+: MA Med Staf Spec Neurologie (9), RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, MUMC+: DA KG Polikliniek (9), Cavaletti, G, Cornblath, D, Merkies, I, Postma, T, Rossi, E, Alberti, P, Bruna, J, Argyriou, A, Briani, C, Velasco, R, Kalofonos, H, Psimaras, D, Ricard, D, Pace, A, Faber, C, Lalisang, R, Brandsma, D, Koeppen, S, Kerrigan, S, Schenone, A, Grisold, W, Mazzeo, A, Padua, L, Dorsey, S, Penas-Prado, M, Valsecchi, M, Bidoli, P, Cazzaniga, M, Neurology, and CCA - Cancer Treatment and quality of life

Subjects
Adult, medicine.medical_specialty, Activities of daily living, side effect, media_common.quotation_subject, medicine.medical_treatment, assessment, chemotherapy, neurotoxicity, patient reported outcome measures, side effects, Medizin, NEUROPATHY CIPN, Neurological examination, Severity of Illness Index, 03 medical and health sciences, Vibration perception, 0302 clinical medicine, Perception, Internal medicine, Activities of Daily Living, medicine, Humans, VALIDITY, media_common, Oncologists, Neuroscience (all), Neurology (clinical), Chemotherapy, medicine.diagnostic_test, business.industry, General Neuroscience, Neurotoxicity, Outcome measures, Peripheral Nervous System Diseases, assessment, chemotherapy, neurotoxicity, patient reported outcome measures, side effects, Adult, Humans, Neurotoxicity Syndromes, Peripheral Nervous System Diseases, Activities of Daily Living, Oncologists, Patient Reported Outcome Measures, Severity of Illness Index, OUTCOME MEASURES, medicine.disease, Peripheral, patient reported outcome measure, 030220 oncology & carcinogenesis, Neurotoxicity Syndromes, business, 030217 neurology & neurosurgery
Abstract

To test if and how chemotherapy-induced peripheral neurotoxicity (CIPN) is perceived differently by patients and physicians, making assessment and interpretation challenging. We performed a secondary analysis of the CI-PeriNomS study which included 281 patients with stable CIPN. We tested: (a) the association between patients' perception of activity limitation in performing eight common tasks and neurological impairment and (b) how the responses to questions related to these daily activities are interpreted by the treating oncologist. To achieve this, we compared patients' perception of their activity limitation with neurological assessment and the oncologists' blind interpretation. Distribution of the scores attributed by oncologists to each daily life maximum limitation ("impossible") generated three groups: Group 1 included limitations oncologists attributed mainly to motor impairment; Group 2 ones mainly attributed to sensory impairment and Group 3 ones with uncertain motor and sensory impairment. Only a subset of questions showed a significant trend between severity in subjective limitation, reported by patients, and neurological impairment. In Group 1, neurological examination confirmed motor impairment in only 51%-65% of patients; 76%-78% of them also had vibration perception impairment. In Group 2, sensory impairment ranged from 84% to 100%; some degree of motor impairment occurred in 43%-56% of them. In Group 3 strength reduction was observed in 49%-50% and sensory perception was altered in up to 82%. Interpretation provided by the panel of experienced oncologists was inconsistent with the neurological impairment. These observations highlight the need of a core set of outcome measures for future CIPN trials.

Published
2019

14. International Guillain-Barré Syndrome Outcome Study

Author

Jacobs, B, van den Berg, B, Verboon, C, Chavada, G, Cornblath, D, Gorson, K, Harbo, T, Hartung, H, Hughes, R, Kusunoki, S, van Doorn, P, Willison, H, Consortium, I, van Woerkom, M, Roodbol, J, Reisin, R, Reddel, S, Islam, Z, Islam, B, Mohammad, Q, van den Bergh, P, Feasby, T, Wang, Y, Péréon, Y, Lehmann, H, Dardiotis, E, Nobile Orazio, E, Shahrizaila, N, Bateman, K, Illa, I, Querol, L, Hsieh, S, Davidson, A, Addington, J, Ajroud Driss, S, Andersen, H, Antonini, G, Attarian, S, Badrising, U, Barroso, F, Benedetti, L, Beronio, A, Bianco, M, Binda, D, Briani, C, Bürmann, J, Bella, I, Bertorini, T, Bhavaraju Sanka, R, Brannagan, T, Busby, M, Butterworth, S, Campagnolo, M, Casasnovas, C, Cavaletti, G, Chao, C, Chen, S, Chetty, S, Claeys, K, Cohen, J, Conti, M, Cosgrove, J, Dalakas, M, Dimachkie, M, Dillmann, U, Domínguez González, C, Doppler, K, Dornonville de la Cour, C, Echaniz Laguna, A, Eftimov, F, Faber, C, Fazio, R, Fokke, C, Fujioka, T, Fulgenzi, E, Galassi, G, Garcia, T, Garnero, M, Garssen, M, Gijsbers, C, Gilchrist, J, Gilhuis, H, Goldstein, J, Goyal, N, Granit, V, Grapperon, A, Gutiérrez Gutiérrez, G, Gutmann, L, Hadden, R, Holbech, J, Holt, J, Homedes Pedret, C, Htut, M, Jellema, K, Jericó Pascual, I, Kaida, K, Karafiath, S, Katzberg, H, Kiers, L, Kieseier, B, Kimpinski, K, Kleyweg, R, Kokubun, N, Kolb, N, Kuitwaard, K, Kuwabara, S, Kwan, J, Ladha, S, Landschoff Lassen, L, Lawson, V, Ledingham, D, Léon Cejas, L, Luciano, C, Lucy, S, Lunn, M, Magot, A, Manji, H, Marchesoni, C, Marfia, Ga, Márquez Infante, C, Martinez Hernandez, E, Mataluni, G, Mattiazi, M, Mcdermott, C, Meekins, G, Miller, J, Monges, M, Montero, M, Morís de la Tassa, G, Nascimbene, C, Neumann, C, Nowak, R, Orizaola Balaguer, P, Osei Bonsu, M, Pan, E, Pardo Fernandez, J, Pasnoor, M, Pulley, M, Rajabally, Y, Rinaldi, S, Ritter, C, Roberts, R, Rojas Marcos, I, Rudnicki, S, Sachs, G, Samijn, J, Santoro, L, Saperstein, D, Savransky, A, Schneider, H, Schenone, A, Sedano Tous, M, Sekiguchi, Y, Sheikh, K, Silvestri, N, Sindrup, S, Sommer, C, Stein, B, Stino, A, Spyropoulos, A, Srinivasan, J, Suzuki, H, Taylor, S, Tankisi, H, Tigner, D, Twydell, P, Valzania, F, van Damme, P, van der Kooi, A, van Dijk, G, van der Ree, T, van Koningsveld, R, Varrato, J, Vermeij, F, Verschuuren, J, Visser, L, Vytopil, M, Waheed, W, Wilken, M, Wilkerson, C, Wirtz, P, Yamagishi, Y, Yiu, E, Zhou, L, Zivkovic, S, Immunology, Neurology, Jacobs, B, van den Berg, B, Verboon, C, Chavada, G, Cornblath, D, Gorson, K, Harbo, T, Hartung, H, Hughes, R, Kusunoki, S, van Doorn, P, Willison, H, van Woerkom, M, Roodbol, J, Reisin, R, Reddel, S, Islam, Z, Islam, B, Mohammad, Q, van den Bergh, P, Feasby, T, Wang, Y, Pã©rã©on, Y, Lehmann, H, Dardiotis, E, Nobile Orazio, E, Shahrizaila, N, Bateman, K, Illa, I, Querol, L, Hsieh, S, Davidson, A, Addington, J, Ajroud Driss, S, Andersen, H, Antonini, G, Attarian, S, Badrising, U, Barroso, F, Benedetti, L, Beronio, A, Bianco, M, Binda, D, Briani, C, Bã¼rmann, J, Bella, I, Bertorini, T, Bhavaraju Sanka, R, Brannagan, T, Busby, M, Butterworth, S, Campagnolo, M, Casasnovas, C, Cavaletti, G, Chao, C, Chen, S, Chetty, S, Claeys, K, Cohen, J, Conti, M, Cosgrove, J, Dalakas, M, Dimachkie, M, Dillmann, U, Domínguez González, C, Doppler, K, Dornonville de la Cour, C, Echaniz Laguna, A, Eftimov, F, Faber, C, Fazio, R, Fokke, C, Fujioka, T, Fulgenzi, E, Galassi, G, Garcia, T, Garnero, M, Garssen, M, Gijsbers, C, Gilchrist, J, Gilhuis, H, Goldstein, J, Goyal, N, Granit, V, Grapperon, A, Gutiérrez Gutiérrez, G, Gutmann, L, Hadden, R, Holbech, J, Holt, J, Homedes Pedret, C, Htut, M, Jellema, K, Jericó Pascual, I, Kaida, K, Karafiath, S, Katzberg, H, Kiers, L, Kieseier, B, Kimpinski, K, Kleyweg, R, Kokubun, N, Kolb, N, Kuitwaard, K, Kuwabara, S, Kwan, J, Ladha, S, Landschoff Lassen, L, Lawson, V, Ledingham, D, Léon Cejas, L, Luciano, C, Lucy, S, Lunn, M, Magot, A, Manji, H, Marchesoni, C, Marfia, G, Márquez Infante, C, Martinez Hernandez, E, Mataluni, G, Mattiazi, M, Mcdermott, C, Meekins, G, Miller, J, Monges, M, Montero, M, Morís de la Tassa, G, Nascimbene, C, Neumann, C, Nowak, R, Orizaola Balaguer, P, Osei Bonsu, M, Pan, E, Pardo Fernandez, J, Pasnoor, M, Pulley, M, Rajabally, Y, Rinaldi, S, Ritter, C, Roberts, R, Rojas Marcos, I, Rudnicki, S, Sachs, G, Samijn, J, Santoro, L, Saperstein, D, Savransky, A, Schneider, H, Schenone, A, Sedano Tous, M, Sekiguchi, Y, Sheikh, K, Silvestri, N, Sindrup, S, Sommer, C, Stein, B, Stino, A, Spyropoulos, A, Srinivasan, J, Suzuki, H, Taylor, S, Tankisi, H, Tigner, D, Twydell, P, Valzania, F, van Damme, P, van der Kooi, A, van Dijk, G, van der Ree, T, van Koningsveld, R, Varrato, J, Vermeij, F, Verschuuren, J, Visser, L, Vytopil, M, Waheed, W, Wilken, M, Wilkerson, C, Wirtz, P, Yamagishi, Y, Yiu, E, Zhou, L, Zivkovic, S, Rehabilitation medicine, Internal medicine, and ANS - Neuroinfection & -inflammation

Subjects
Male, Pediatrics, PROGNOSIS, diagnosis, International Cooperation, Guillain-Barré syndrome, biomarkers, outcome, prognosis, treatment, Guillain-Barre syndrome, Guillain-Barré syndrome, Neuroscience (all), Neurology (clinical), Cohort Studies, 0302 clinical medicine, Epidemiology, Outcome Assessment, Health Care, INFECTION, CRITERIA, 030212 general & internal medicine, General Neuroscience, Biobank, Observational Studies as Topic, diagnosi, Disease Progression, biomarker, Female, Settore MED/26 - Neurologia, medicine.symptom, prognosi, Cohort study, medicine.medical_specialty, Weakness, Guillain-Barre Syndrome, CLASSIFICATION, VALIDATION, 03 medical and health sciences, medicine, Humans, INTRAVENOUS IMMUNOGLOBULIN, Protocol (science), business.industry, Polyradiculoneuropathy, medicine.disease, ANTIBODIES, Observational study, business, COLLECTION, 030217 neurology & neurosurgery
Abstract

Guillain-Barré syndrome (GBS) is an acute polyradiculoneuropathy with a highly variable clinical presentation, course, and outcome. The factors that determine the clinical variation of GBS are poorly understood which complicates the care and treatment of individual patients. The protocol of the ongoing International GBS Outcome Study (IGOS), a prospective, observational, multicenter cohort study that aims to identify the clinical and biological determinants and predictors of disease onset, subtype, course and outcome of GBS is presented here. Patients fulfilling the diagnostic criteria for GBS, regardless of age, disease severity, variant forms, or treatment, can participate if included within 2 weeks after onset of weakness. Information about demography, preceding infections, clinical features, diagnostic findings, treatment, course, and outcome is collected. In addition, cerebrospinal fluid and serial blood samples for serum and DNA is collected at standard time points. The original aim was to include at least 1,000 patients with a follow-up of 1-3 years. Data are collected via a web-based data entry system and stored anonymously. IGOS started in May 2012 and by January 2017 included more than 1,400 participants from 143 active centers in 19 countries across 5 continents. The IGOS data/biobank is available for research projects conducted by expertise groups focusing on specific topics including epidemiology, diagnostic criteria, clinimetrics, electrophysiology, antecedent events, antibodies, genetics, prognostic modeling, treatment effects, and long-term outcome of GBS. The IGOS will help to standardize the international collection of data and biosamples for future research of GBS.

Published
2017

17. Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin

Author

Alberti, P., Rossi, E., Cornblath, D. R., Merkies, I. S. J., Postma, T. J., Frigeni, B., Bruna, J., Velasco, R., Argyriou, A. A., Kalofonos, H. P., Psimaras, D., Ricard, D., Pace, A., Galiè, E., Briani, C., Dalla Torre, C., Faber, C. G., Lalisang, R. I., Boogerd, W., Brandsma, D., Koeppen, S., Hense, J., Storey, D., Kerrigan, S., Schenone, A., Fabbri, S., Valsecchi, M. G., Cavaletti, G., Cavaletti, G., Cornblath, D.R., Merkies, I.S.J., Postma, T.J., Valsecchi, M.G, Galimberti, S., Rossi, E., Cavaletti, G., Frigeni, B., Lanzani, F., Mattavelli, L., Piatti, ML., Alberti, P., Binda, D., Bidoli, P.., Cazzaniga, M., Cortinovis, D., Bruna, J., Velasco, R., Argyriou, AA., Kalofonos, HP., Psimaras, D., Ricard, D., Pace, A., Galiè, E., Briani, C., Lucchetta, M., Campagnolo, M., Dalla Torre, C., Merkies, ISJ., Faber, CG., Merkies, ISJ., Vanhoutte, EK., Bakkers, M., Brouwer, B., Lalisang, RI., Boogerd, W., Brandsma, D., Koeppen, S., Hense, J., Grant, R., Storey, D., Kerrigan, S., Schenone, A., Reni, L., Piras, B., Fabbri, S., Padua, L., Granata, G., Leandri, M., Ghignotti, I., Plasmati, R.., Pastorelli, F., Postma, TJ., Heimans, JJ., Eurelings, M., Meijer, RJ., Grisold, W., Lindeck Pozza, E., Mazzeo, A., Toscano, A., Tomasello, C., Altavilla, G., Penas Prado, M., Dominguez Gonzalez, C., Dorsey, SG., and Brell, JM.

Published
2014
Full Text
View/download PDF

19. Sporadic hereditary neuropathies misdiagnosed as chronic inflammatory demyelinating polyradiculoneuropathy: Pitfalls and red flags

Author

Campagnolo, M., Taioli, F., Cacciavillani, M., Ruiz, M., Luigetti, Marco, Salvalaggio, A., Castellani, F., Testi, S., Ferrarini, M., Cavallaro, T., Gasparotti, R., Fabrizi, G. M., Briani, C., Luigetti M. (ORCID:0000-0001-7539-505X), Campagnolo, M., Taioli, F., Cacciavillani, M., Ruiz, M., Luigetti, Marco, Salvalaggio, A., Castellani, F., Testi, S., Ferrarini, M., Cavallaro, T., Gasparotti, R., Fabrizi, G. M., Briani, C., and Luigetti M. (ORCID:0000-0001-7539-505X)

Abstract

Hereditary neuropathies may be misdiagnosed with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). A correct diagnosis is crucial for avoiding unnecessary therapies and access genetic counseling. We report on nine patients (seven men, mean age 49.2 ± 16.1) diagnosed with and treated as CIDP, in whom mutations or variants of unknown significance (VUS) in genes associated with hereditary neuropathies were reported. All underwent neurological and neurophysiological examination, eight also cerebrospinal fluid (CSF) analysis. In 4/9, nerve ultrasound and/or MR-neurography were performed. All the patients complained of progressive upper or lower limbs sensory-motor symptoms, with heterogeneous disease duration (1-34 years, mean 8.6 ± 10.8). Neurophysiology showed demyelinating signs in seven patients, mixed findings with predominant axonal damage in two patients. Neuroimaging disclosed diffuse abnormalities at proximal and distal segments. Molecular screening showed PMP22 duplication in two patients, mutations in the MPZ, EGR2, and GJB1 genes were reported in each of the remaining patients. The two patients with mixed neurophysiological findings had p.Val30Met mutation in the transthyretin gene. Two patients had VUS in the MARS and HSPB1 genes. Four patients had partial response to immunomodulant therapies, and CSF and neurophysiological features suggesting an inflammatory condition concomitant with the hereditary neuropathy. Hereditary neuropathy may be misdiagnosed with CIDP. The most common pitfalls are CSF (high protein levels and oligoclonal bands), incorrect interpretation of neurophysiology, and transient benefit from therapies. Neuroimaging may be helpful in cases with atypical presentations or when severe axonal damage complicate the neurophysiological interpretation.

Published
2020

20. Nerve ultrasound in hereditary transthyretin amyloidosis: red flags and possible progression biomarkers

Author

Salvalaggio, A., Coraci, Daniele, Cacciavillani, M., Obici, L., Mazzeo, A., Luigetti, Marco, Pastorelli, F., Grandis, M., Cavallaro, T., Bisogni, G., Lozza, A., Gemelli, C., Gentile, L., Ermani, M., Fabrizi, G. M., Plasmati, R., Campagnolo, M., Castellani, F., Gasparotti, Roberto, Martinoli, C., Padua, Luca, Briani, C., Coraci D., Luigetti M. (ORCID:0000-0001-7539-505X), Gasparotti R., Padua L. (ORCID:0000-0003-2570-9326), Salvalaggio, A., Coraci, Daniele, Cacciavillani, M., Obici, L., Mazzeo, A., Luigetti, Marco, Pastorelli, F., Grandis, M., Cavallaro, T., Bisogni, G., Lozza, A., Gemelli, C., Gentile, L., Ermani, M., Fabrizi, G. M., Plasmati, R., Campagnolo, M., Castellani, F., Gasparotti, Roberto, Martinoli, C., Padua, Luca, Briani, C., Coraci D., Luigetti M. (ORCID:0000-0001-7539-505X), Gasparotti R., and Padua L. (ORCID:0000-0003-2570-9326)

Abstract

Background: Diagnostic delay of hereditary transthyretin amyloidosis (ATTRv, v for variant) prevents timely treatment and, therefore, concurs to the mortality of the disease. The aim of the present study was to explore with nerve ultrasound (US) possible red flags for early diagnosis in ATTRv patients with carpal tunnel syndrome (CTS) and/or polyneuropathy and in pre-symptomatic carriers. Methods: Patients and pre-symptomatic carriers with a TTR gene mutation were enrolled from seven Italian centers. Severity of CTS was assessed with neurophysiology and clinical evaluation. Median nerve cross-section area (CSA) was measured with US in ATTRv carriers with CTS (TTR-CTS). One thousand one hundred ninety-six idiopathic CTS were used as controls. Nerve US was also performed in several nerve trunks (median, ulnar, radial, brachial plexi, tibial, peroneal, sciatic, sural) in ATTRv patients with polyneuropathy and in pre-symptomatic carriers. Results: Sixty-two subjects (34 men, 28 women, mean age 59.8 years ± 12) with TTR gene mutation were recruited. With regard to CTS, while in idiopathic CTS there was a direct correlation between CTS severity and median nerve CSA (r = 0.55, p < 0.01), in the subgroup of TTR-CTS subjects (16 subjects, 5 with bilateral CTS) CSA did not significantly correlate with CTS severity (r = − 0.473). ATTRv patients with polyneuropathy showed larger CSA than pre-symptomatic carriers in several nerve sites, more pronounced at brachial plexi (p < 0.001). Conclusions: The present study identifies nerve morphological US patterns that may help in the early diagnosis (morpho-functional dissociation of median nerve in CTS) and monitoring of pre-symptomatic TTR carriers (larger nerve CSA at proximal nerve sites, especially at brachial plexi).

Published
2020

22. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings

Author

Cavaletti, G., Cornblath, D. R., Merkies, I. S. J., Postma, T. J., Rossi, E., Frigeni, B., Alberti, P., Bruna, J., Velasco, R., Argyriou, A. A., Kalofonos, H. P., Psimaras, D., Ricard, D., Pace, A., Galiè, E., Briani, C., Dalla Torre, C., Faber, C. G., Lalisang, R. I., Boogerd, W., Brandsma, D., Koeppen, S., Hense, J., Storey, D., Kerrigan, S., Schenone, A., Fabbri, S., Valsecchi, M. G., Mazzeo, A., Pace, A., Pessino, A., Schenone, A., Toscano, A., Argyriou, A.A., Brouwer, B., Frigeni, B., Piras, B., Briani, C., Dalla Torre, C., Dominguez Gonzalez, C., Faber, C. G., Tomasello, C., Binda, D., Brandsma, D., Cortinovis, D., Psimaras, D., Ricard, D., Storey, D., Cornblath, D.R., Galiè, E., Lindeck Pozza, E., Rossi, E., Vanhoutte, E.K., Lanzani, F., Pastorelli, F., Altavilla, G., Cavaletti, G., Granata, G., Kalofonos, H.P., Ghignotti, I., Merkies, I.S.J., Bruna, J., Hense, J., Heimans, J.J., Mattavelli, L., Padua, L., Reni, L., Bakkers, M., Boogerd, M., Campagnolo, M., Cazzaniga, M., Eurelings, M., Leandri, M., Lucchetta, M., Penas Prado, M., Russo, M., Valsecchi, M.G., Piatti, M.L., Alberti, P., Bidoli, P., Grant, R., Plasmati, R., Velasco, R., Lalisang, R.I., Meijer, R.J., Fabbri, S., Dorsey, S. G., Galimberti, S., Kerrigan, S., Koeppen, S., Postma, T.J., Boogerd, W., and Grisold, W.

Published
2013
Full Text
View/download PDF

24. Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve

Author

Alberti, P, Rossi, E, Argyriou, A, Kalofonos, H, Briani, C, Cacciavillani, M, Campagnolo, M, Bruna, J, Velasco, R, Cazzaniga, M, Cortinovis, D, Valsecchi., M, Cavaletti, G, Argyriou, AA, Kalofonos, HP, Cazzaniga, ME, Valsecchi. MG, Alberti, P, Rossi, E, Argyriou, A, Kalofonos, H, Briani, C, Cacciavillani, M, Campagnolo, M, Bruna, J, Velasco, R, Cazzaniga, M, Cortinovis, D, Valsecchi., M, Cavaletti, G, Argyriou, AA, Kalofonos, HP, Cazzaniga, ME, and Valsecchi. MG

Abstract

Purpose: We aimed to verify the predictiveness of dorsal sural nerve neurophysiological monitoring in obtaining risk stratification for oxaliplatin-induced peripheral neurotoxicity (OXAPN). Methods: We conducted a secondary analysis on a cohort of 110 colorectal cancer patients who were evaluated clinically and neurophysiologically before chemotherapy, at mid-treatment and at discontinuation. We applied the classification tree analysis method to predict the end-of-treatment OXAPN neurophysiological diagnosis, using data recorded at mid-treatment. We then ascertained the correlation between the obtained classes and neurological impairment at the end of treatment (Fisher’s exact test). Results: Dorsal sural nerve monitoring enabled us to stratify oxaliplatin-treated patients into risk classes with an implemented approach to neurophysiology application in this setting. Neurological outcome at discontinuation was predicted by neurophysiological monitoring performed during chemotherapy administration. Conclusions: We demonstrated the role that neurophysiology may play in clinical trials as an early surrogate marker that can predict OXAPN development at the end of treatment. Specifically, we propose abnormal dorsal sural sensory nerve testing as an early biomarker in identifying patients at high risk of eventually developing OXAPN.

Published
2018

25. PREVALENCE OF ANTI-NEUROFASCIN-155, ANTI-CONTACTIN-1 AND CONTACTIN-ASSOCIATED PROTEIN 1 ANTIBODIES IN CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY: A SEROLOGICAL MULTICENTER STUDY IN ITALY

Author

Callegari, I., Cortese, A., Lauria, G., Briani, C., Luigetti, M., Fazio, R., Benedetti, L., Marfia, G., Clerici, M., Carpo, M., Corbo, M., Mazzeo, A., Ferrari, S., Giannini, F., Man-Ganelli, F., Manso, C., Claudia Giannotta, Berardinelli, A., Zardini, E., Romagnolo, S., Curro, R., Gastaldi, M., Spina, E., Topa, A., Dacci, P., Lombardi, R., Campagnolo, M., Bisogni, G., Cerri, F., De, Michelis C., Mataluni, G., Stancanelli, C., Mariotto, S., Piccolo, L., Schenone, A., Moglia, A., Marchioni, E., Nobile-Orazio, E., Devaux, J., and Franciotta, D.

Subjects
Settore MED/26 - Neurologia
Published
2017

26. PREVALENCE OF ANTI-NEUROFASCIN-155, ANTI-CONTACTIN-1 AND ANTI-CONTACTIN-ASSOCIATED PROTEIN-1 ANTIBODIES IN CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY: A SEROLOGICAL MULTICENTER STUDY IN ITALY

Author

Cortese, A., Callegari, I., Lauria, G., Briani, C., Luigetti, M., Fazio, R., Benedetti, L., Marfia, G., Clerici, M., Carpo, M., Corbo, M., Mazzeo, A., Ferrari, S., Giannini, F., Manso, C., Claudia Giannotta, Berardinelli, A., Zardini, E., Romagnolo, S., Dacci, P., Lombardi, R., Campagnolo, M., Bisogni, G., Cerri, F., Michelis, C., Mataluni, G., Stancanelli, C., Mariotto, S., Curro, R., Piccolo, L., Schenone, A., Moglia, A., Marchioni, E., Nobile-Orazio, E., Devaux, J., and Franciotta, D.

Subjects
Settore MED/26 - Neurologia
Published
2017

27. Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the CI-PeriNomS study

Author

Griffith, K. A., Dorsey, S. G., Renn, C. L., Zhu, S., Johantgen, M. E., Cornblath, D. R., Argyriou, A. A., Cavaletti, G., Merkies, I. S. J., Alberti, P., Postma, T. J., Rossi, E., Frigeni, B., Bruna, J., Velasco, R., Kalofonos, H. P., Psimaras, D., Ricard, D., Pace, A., Galie, E., Briani, C., Dalla Torre, C., Faber, C. G., Lalisang, R. I., Boogerd, W., Brandsma, D., Koeppen, S., Hense, J., Storey, D. J., Kerrigan, S., Schenone, A., Fabbri, S., Valsecchi, M. G., Galimberti, S., Lucchetta, M., Campagnolo, M., Vanhoutte, E. K., Bakkers, M., Brouwer, B., Grant, R., Reni, L., Piras, B., Lanzani, F., Mattavelli, L., Piatti, M. L., Binda, P., Bidoli, P., Cazzaniga, M., Cortinovis, D., Pessino, A., Padua, L., Granata, G., Leandri, M., Ghignotti, I., Plasmati, R., Pastorelli, F., Heimans, J. J., Eurelings, M., Meijer, R. J., Grisold, W., Lindeck, E., Mazzeo, A., Toscano, A., Russo, M., Tomasello, C., Altavill, G., Penas Prado, M., Dominguez Gonzalez, C., Brell, J., Interne Geneeskunde, RS: CARIM - R3 - Vascular biology, RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, RS: GROW - Oncology, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Klinische Neurowetenschappen, Griffith, K, Dorsey, S, Renn, C, Zhu, S, Johantgen, M, Cornblath, D, Argyriou, A, Cavaletti, G, Merkies, I, Alberti, P, Postma, T, Rossi, E, Frigeni, B, Bruna, J, Velasco, R, Kalofonos, H, Psimaras, D, Ricard, D, Pace, A, Galie, E, Briani, C, Torre, C, Faber, C, Lalisang, R, Boogerd, W, Brandsma, D, Koeppen, S, Hense, J, Storey, D, Kerrigan, S, Schenone, A, Fabbri, S, Valsecchi, M, Bidoli, P, Neurology, and CCA - Innovative therapy

Subjects
Male, medicine.medical_specialty, peripheral neuropathy, Drug-Related Side Effects and Adverse Reactions, assessment, Medizin, Neural Conduction, Neurophysiology, Action Potentials, Datasets as Topic, Sural nerve, Logistic regression, chemotherapy, Article, Assessment, Chemotherapy, Peripheral neuropathy, Aged, Drug Therapy, Female, Humans, Linear Models, Middle Aged, Pain Measurement, Peripheral Nervous System Diseases, Sural Nerve, Neurologic Examination, Neuroscience (all), Neurology (clinical), Neurofisiologia, Secondary analysis, Quimioteràpia, Medicine, business.industry, General Neuroscience, medicine.disease, Confidence interval, Surgery, Chemotherapy-induced peripheral neuropathy, Anesthesia, Abnormality, neurophysiology, business
Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) lacks standardized clinical measurement. The objective of the current secondary analysis was to examine data from the CIPN Outcomes Standardization (CI-PeriNomS) study for associations between clinical examinations and neurophysiological abnormalities. Logistic regression estimated the strength of associations of vibration, pin, and monofilament examinations with lower limb sensory and motor amplitudes. Examinations were classified as normal (0), moderately abnormal (1), or severely abnormal (2). Among 218 participants, those with class 1 upper extremity (UE) and classes 1 or 2 lower extremity (LE) monofilament abnormality were 2.79 (95% confidence interval [CI]: 1.28-6.07), 3.49 (95%CI: 1.61-7.55), and 4.42 (95%CI: 1.35-14.46) times more likely to have abnormal sural nerve amplitudes, respectively, compared to individuals with normal examinations. Likewise, those with class 2 UE and classes 1 or 2 LE vibration abnormality were 8.65 (95%CI: 1.81-41.42), 2.54 (95%CI: 1.19-5.41), and 7.47 (95%CI: 2.49-22.40) times more likely to have abnormal sural nerve amplitudes, respectively, compared to participants with normal examinations. Abnormalities in vibration and monofilament examinations are associated with abnormal sural nerve amplitudes and are useful in identifying CIPN.

Published
2014

28. Following up the long-term Course of Oxaliplatin-Induced Peripheral Neurotoxicity

Author

Paola Alberti, Izquierdo, C., Campagnolo, M., Velasco, R., Cacciavillani, M., Bruna, J., Cavaletti, G., Briani, C., Argyriou, A. A., Alberti, P, Izquierdo, C, Campagnolo, M, Velasco, R, Caccavillani, M, Bruna, J, Cavaletti, G, Briani, C, and Argyriou, A

Subjects
Long-Term Toxicity, Oxaliplatin, Neurotoxicity
Published
2015

30. International Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome

Author

Jacobs, B.C. (Bart C.), Berg, B. (Bianca) van den, Verboon, C. (Christine), Chavada, G. (Govindsinh), Cornblath, D.R. (David), Gorson, K.C. (Kenneth), Harbo, T. (Thomas), Hartung, H.P., Hughes, R.A.C. (Richard A. C.), Kusunoki, S. (Susumu), Doorn, P.A. (Pieter) van, Willison, H.J. (Hugh J.), Jacobs, B.C. (Bart), Hughes, R.A.C. (Richard), Cornblath, D.R., Gorson, K.C., Kusunoki, S., Willison, H.J. (Hugh), van Woerkom, M., van den Berg, B., Verboon, C., Roodbol, J. (J.), Reisin, R. (R.), Reddel, S.W., Islam, Z. (Zhahirul), Islam, B., Mohammad, Q.D. (Quazi), Bergh, P.Y.K. (Paul) van den, Feasby, T.E., Wang, Y.Z., Harbo, T., Péréon, Y., Lehmann, H.C., Dardiotis, E., Nobile-Orazio, E. (Eduarde), Shahrizaila, N., Jacobs, B.C., Bateman, K., Illa, I. (Isabel), Querol, L. (Luis), Hsieh, S.T., Willison, H.J., Chavada, G., Davidson, A., Addington, J.M., Ajroud-Driss, S., Andersen, H., Antonini, G., Attarian, S., Badrising, U.A. (Umesh), Barroso, F.A., Benedetti, L., Beronio, A., Bianco, M., Binda, D., Briani, C., Bürmann, J., Bella, I.R., Bertorini, T.E., Bhavaraju-Sanka, R., Brannagan, T.H., Busby, M., Butterworth, S., Campagnolo, M., Casasnovas, C., Cavaletti, G., Chao, C.S., Chen, S., Chetty, S., Claeys, T. (Tine), Cohen, J.A., Conti, M.E., Cosgrove, J.S., Dalakas, M.C. (Marinos), Dimachkie, M.M., Dillmann, U., Domínguez González, C., Doppler, K., Dornonville de la Cour, C., Echaniz-Laguna, A., Eftimov, F. (Filip), Faber, C.G., Fazio, R. (R.), Fokke, M. (Maureen), Fujioka, T., Fulgenzi, E. (E.), Galassi, G., Garcia, T., Garnero, M., Garssen, M.P.J. (Marcel), Gijsbers, C.J., Gilchrist, J.M., Gilhuis, J. (Job), Goldstein, J.M., Goyal, N., Granit, V., Grapperon, A., Gutiérrez Gutiérrez, G., Gutmann, L., Hadden, R.D.M. (Rob), Holbech, J.V., Holt, J.K.L., Homedes Pedret, C., Htut, M., Jellema, K., Jericó Pascual, I., Kaida, K.I. (Ken Ichi), Karafiath, S., Katzberg, H. (Hans), Kiers, H.A.L. (Henk), Kieseier, B.C. (Bernd), Kimpinski, K., Kleyweg, R.P., Kokubun, N., Kolb, N.A., Kuitwaard, K. (Krista), Kuwabara, S., Kwan, J.Y., Ladha, S.S., Landschoff Lassen, L., Lawson, V., Ledingham, D., Léon Cejas, L., Luciano, C.A., Lucy, S.T., Lunn, M.P.T. (Michael P. T.), Magot, A., Manji, H., Marchesoni, A., Marfia, G.A.M., Márquez Infante, C., Martinez Hernandez, E., Mataluni, G., Mattiazi, M., McDermott, C.J., Meekins, G.D., Miller, J., Monges, M.S., Montero, M.C.J., Morís de la Tassa, G., Nascimbene, C., Neumann, C., Nowak, R.J., Orizaola Balaguer, P., Osei-Bonsu, M., Pan, E.B.L., Pardo Fernandez, J., Pasnoor, M., Pulley, M.T., Rajabally, Y.A., Rinaldi, S. (Sabina), Ritter, C., Roberts, R.C., Rojas-Marcos, I., Rudnicki, S.A., Sachs, G.M., Samijn, J.P. (Johnny), Santoro, L., Saperstein, D.S., Savransky, A., Schneider, H., Schenone, A. (Andrea), Sedano Tous, M.J., Sekiguchi, Y., Sheikh, K.A., Silvestri, N.J., Sindrup, S.H., Sommer, C., Stein, B., Stino, A.M., Spyropoulos, A., Srinivasan, J., Suzuki, H., Taylor, S.W., Tankisi, H., Tigner, D., Twydell, P.T., Valzania, F., van Damme, P., Kooj, A.J. (Anneke), Dijk, G.W. (Gert) van, van der Ree, T., Koningsveld, R. (Rinske) van, Varrato, J.D., Vermeij, F.H. (Frederique), Verschuuren, J.J. (Jan), Visser, L.H. (Leendert), Vytopil, M.V., Waheed, W., Wilken, M., Wilkerson, C., Wirtz, P.W., Yamagishi, Y., Yiu, E.M., Zhou, L., Zivkovic, S.A. (Sasa), Jacobs, B.C. (Bart C.), Berg, B. (Bianca) van den, Verboon, C. (Christine), Chavada, G. (Govindsinh), Cornblath, D.R. (David), Gorson, K.C. (Kenneth), Harbo, T. (Thomas), Hartung, H.P., Hughes, R.A.C. (Richard A. C.), Kusunoki, S. (Susumu), Doorn, P.A. (Pieter) van, Willison, H.J. (Hugh J.), Jacobs, B.C. (Bart), Hughes, R.A.C. (Richard), Cornblath, D.R., Gorson, K.C., Kusunoki, S., Willison, H.J. (Hugh), van Woerkom, M., van den Berg, B., Verboon, C., Roodbol, J. (J.), Reisin, R. (R.), Reddel, S.W., Islam, Z. (Zhahirul), Islam, B., Mohammad, Q.D. (Quazi), Bergh, P.Y.K. (Paul) van den, Feasby, T.E., Wang, Y.Z., Harbo, T., Péréon, Y., Lehmann, H.C., Dardiotis, E., Nobile-Orazio, E. (Eduarde), Shahrizaila, N., Jacobs, B.C., Bateman, K., Illa, I. (Isabel), Querol, L. (Luis), Hsieh, S.T., Willison, H.J., Chavada, G., Davidson, A., Addington, J.M., Ajroud-Driss, S., Andersen, H., Antonini, G., Attarian, S., Badrising, U.A. (Umesh), Barroso, F.A., Benedetti, L., Beronio, A., Bianco, M., Binda, D., Briani, C., Bürmann, J., Bella, I.R., Bertorini, T.E., Bhavaraju-Sanka, R., Brannagan, T.H., Busby, M., Butterworth, S., Campagnolo, M., Casasnovas, C., Cavaletti, G., Chao, C.S., Chen, S., Chetty, S., Claeys, T. (Tine), Cohen, J.A., Conti, M.E., Cosgrove, J.S., Dalakas, M.C. (Marinos), Dimachkie, M.M., Dillmann, U., Domínguez González, C., Doppler, K., Dornonville de la Cour, C., Echaniz-Laguna, A., Eftimov, F. (Filip), Faber, C.G., Fazio, R. (R.), Fokke, M. (Maureen), Fujioka, T., Fulgenzi, E. (E.), Galassi, G., Garcia, T., Garnero, M., Garssen, M.P.J. (Marcel), Gijsbers, C.J., Gilchrist, J.M., Gilhuis, J. (Job), Goldstein, J.M., Goyal, N., Granit, V., Grapperon, A., Gutiérrez Gutiérrez, G., Gutmann, L., Hadden, R.D.M. (Rob), Holbech, J.V., Holt, J.K.L., Homedes Pedret, C., Htut, M., Jellema, K., Jericó Pascual, I., Kaida, K.I. (Ken Ichi), Karafiath, S., Katzberg, H. (Hans), Kiers, H.A.L. (Henk), Kieseier, B.C. (Bernd), Kimpinski, K., Kleyweg, R.P., Kokubun, N., Kolb, N.A., Kuitwaard, K. (Krista), Kuwabara, S., Kwan, J.Y., Ladha, S.S., Landschoff Lassen, L., Lawson, V., Ledingham, D., Léon Cejas, L., Luciano, C.A., Lucy, S.T., Lunn, M.P.T. (Michael P. T.), Magot, A., Manji, H., Marchesoni, A., Marfia, G.A.M., Márquez Infante, C., Martinez Hernandez, E., Mataluni, G., Mattiazi, M., McDermott, C.J., Meekins, G.D., Miller, J., Monges, M.S., Montero, M.C.J., Morís de la Tassa, G., Nascimbene, C., Neumann, C., Nowak, R.J., Orizaola Balaguer, P., Osei-Bonsu, M., Pan, E.B.L., Pardo Fernandez, J., Pasnoor, M., Pulley, M.T., Rajabally, Y.A., Rinaldi, S. (Sabina), Ritter, C., Roberts, R.C., Rojas-Marcos, I., Rudnicki, S.A., Sachs, G.M., Samijn, J.P. (Johnny), Santoro, L., Saperstein, D.S., Savransky, A., Schneider, H., Schenone, A. (Andrea), Sedano Tous, M.J., Sekiguchi, Y., Sheikh, K.A., Silvestri, N.J., Sindrup, S.H., Sommer, C., Stein, B., Stino, A.M., Spyropoulos, A., Srinivasan, J., Suzuki, H., Taylor, S.W., Tankisi, H., Tigner, D., Twydell, P.T., Valzania, F., van Damme, P., Kooj, A.J. (Anneke), Dijk, G.W. (Gert) van, van der Ree, T., Koningsveld, R. (Rinske) van, Varrato, J.D., Vermeij, F.H. (Frederique), Verschuuren, J.J. (Jan), Visser, L.H. (Leendert), Vytopil, M.V., Waheed, W., Wilken, M., Wilkerson, C., Wirtz, P.W., Yamagishi, Y., Yiu, E.M., Zhou, L., and Zivkovic, S.A. (Sasa)

Abstract

Guillain-Barré syndrome (GBS) is an acute polyradiculoneuropathy with a highly variable clinical presentation, course, and outcome. The factors that determine the clinical variation of GBS are poorly understood which complicates the care and treatment of individual patients. The protocol of the ongoing International GBS Outcome Study (IGOS), a prospective, observational, multicenter cohort study that aims to identify the clinical and biological determinants and predictors of disease onset, subtype, course and outcome of GBS is presented here. Patients fulfilling the diagnostic criteria for GBS, regardless of age, disease severity, variant forms, or treatment, can participate if included within 2 weeks after onset of weakness. Information about demography, preceding infections, clinical features, diagnostic findings, treatment, course, and outcome is collected. In addition, cerebrospinal fluid and serial blood samples for serum and DNA is collected at standard time points. The original aim was to include at least 1,000 patients with a follow-up of 1–3 years. Data are collected via a web-based data entry system and stored anonymously. IGOS started in May 2012 and by January 2017 included more than 1,400 participants from 143 active centers in 19 countries across 5 continents. The IGOS data/biobank is available for research projects conducted by expertise groups focusing on specific topics including epidemiology, diagnostic criteria, clinimetrics, electrophysiology, antecedent events, antibodies, genetics, prognostic modeling, treatment effects, and long-term outcome of GBS. The IGOS will help to standardize the international collection of data and biosamples for future research of GBS.

Published
2017
Full Text
View/download PDF

31. Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20)

Author

Kieffer, J, Postma, T, van de Poll Franse, L, Mols, F, Heimans, J, Cavaletti, G, Aaronson, N, Cornblath, D, Merkies, I, Valsecchi, M, Galimberti, S, Rossi, E, Frigeni, B, Lanzani, F, Mattavelli, L, Piatti, M, Alberti, P, Binda, D, Bidoli, P, Cazzaniga, M, Cortinovis, D, Bruna, J, Velasco, R, Argyriou, A, Kalofonos, H, Psimaras, D, Ricard, D, Pace, A, Galiã ̈, E, Briani, C, Lucchetta, M, Campagnolo, M, Torre, C, Faber, C, Vanhoutte, E, Bakkers, M, Brouwer, B, Boogerd, M, Lalisang, R, Boogerd, W, Brandsma, D, Koeppen, S, Hense, J, Grant, R, Storey, D, Kerrigan, S, Schenone, A, Reni, L, Piras, B, Fabbri, S, Pessino, A, Padua, L, Granata, G, Leandri, M, Ghignotti, I, Plasmati, R, Pastorelli, F, Eurelings, M, Meijer, R, Grisold, W, Pozza, E, Mazzeo, A, Toscano, A, Russo, M, Tomasello, C, Altavilla, G, Prado, M, Gonzalez, C, Dorsey, S, CAVALETTI, GUIDO ANGELO, VALSECCHI, MARIA GRAZIA, FRIGENI, BARBARA, LANZANI, FRANCESCA, MATTAVELLI, LAURA, ALBERTI, PAOLA, BINDA, DAVIDE, BIDOLI, PAOLO, CORTINOVIS, DIEGO LUIGI, Dorsey, S., Kieffer, J, Postma, T, van de Poll Franse, L, Mols, F, Heimans, J, Cavaletti, G, Aaronson, N, Cornblath, D, Merkies, I, Valsecchi, M, Galimberti, S, Rossi, E, Frigeni, B, Lanzani, F, Mattavelli, L, Piatti, M, Alberti, P, Binda, D, Bidoli, P, Cazzaniga, M, Cortinovis, D, Bruna, J, Velasco, R, Argyriou, A, Kalofonos, H, Psimaras, D, Ricard, D, Pace, A, Galiã ̈, E, Briani, C, Lucchetta, M, Campagnolo, M, Torre, C, Faber, C, Vanhoutte, E, Bakkers, M, Brouwer, B, Boogerd, M, Lalisang, R, Boogerd, W, Brandsma, D, Koeppen, S, Hense, J, Grant, R, Storey, D, Kerrigan, S, Schenone, A, Reni, L, Piras, B, Fabbri, S, Pessino, A, Padua, L, Granata, G, Leandri, M, Ghignotti, I, Plasmati, R, Pastorelli, F, Eurelings, M, Meijer, R, Grisold, W, Pozza, E, Mazzeo, A, Toscano, A, Russo, M, Tomasello, C, Altavilla, G, Prado, M, Gonzalez, C, Dorsey, S, CAVALETTI, GUIDO ANGELO, VALSECCHI, MARIA GRAZIA, FRIGENI, BARBARA, LANZANI, FRANCESCA, MATTAVELLI, LAURA, ALBERTI, PAOLA, BINDA, DAVIDE, BIDOLI, PAOLO, CORTINOVIS, DIEGO LUIGI, and Dorsey, S.

Abstract

To investigate the scale structure and psychometrics of the EORTC chemotherapy-induced peripheral neuropathy module (QLQ-CIPN20).Using confirmatory factor analyses (CFA), we tested two hypothesized scale structure models of the QLQ-CIPN20 in 473 patients with non-small cell lung cancer, 281 patients with heterogeneous cancer diagnoses, and 500 patients with colorectal cancer. We also modeled the two hypothesized models as bi-factor models. These included a general factor, in addition to the specific domain factors. Additional models were investigated with exploratory factor analysis (EFA). Known groups validity was evaluated where justified.CFA could not confirm the two hypothesized models (Model 1: CFI < 0.926; TLI < 0.914; RMSEA > 0.077 and Model 2: CFI < 0.906; TLI < 0.887; RMSEA > 0.105) in any of the three samples. Including a general factor to these two hypothesized models to produce a bi-factor model also did not yield satisfactory results. Using EFA, we identified four different factor structures in the three samples that were unstable due to cross loadings of the items. When scoring the QLQ-CIPN20 as a simple, additive checklist evidence was found for known groups validity in the first two samples based on Common Toxicity Criteria (CTC-AE), and in the third sample based on exposure to CIPN-inducing chemotherapy.Neither CFA nor EFA yielded support for a stable subscale structure for the QLQ-CIPN20. Scoring the questionnaire as a simple additive checklist results in acceptable validity.

Published
2017

32. International Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome

Author

Jacobs, B, van den Berg, B, Verboon, C, Chavada, G, Cornblath, D, Gorson, K, Harbo, T, Hartung, H, Hughes, R, Kusunoki, S, van Doorn, P, Willison, H, van Woerkom, M, Roodbol, J, Reisin, R, Reddel, S, Islam, Z, Islam, B, Mohammad, Q, van den Bergh, P, Feasby, T, Wang, Y, Pã©rã©on, Y, Lehmann, H, Dardiotis, E, Nobile Orazio, E, Shahrizaila, N, Bateman, K, Illa, I, Querol, L, Hsieh, S, Davidson, A, Addington, J, Ajroud Driss, S, Andersen, H, Antonini, G, Attarian, S, Badrising, U, Barroso, F, Benedetti, L, Beronio, A, Bianco, M, Binda, D, Briani, C, Bã1⁄4rmann, J, Bella, I, Bertorini, T, Bhavaraju Sanka, R, Brannagan, T, Busby, M, Butterworth, S, Campagnolo, M, Casasnovas, C, Cavaletti, G, Chao, C, Chen, S, Chetty, S, Claeys, K, Cohen, J, Conti, M, Cosgrove, J, Dalakas, M, Dimachkie, M, Dillmann, U, Domínguez González, C, Doppler, K, Dornonville de la Cour, C, Echaniz Laguna, A, Eftimov, F, Faber, C, Fazio, R, Fokke, C, Fujioka, T, Fulgenzi, E, Galassi, G, Garcia, T, Garnero, M, Garssen, M, Gijsbers, C, Gilchrist, J, Gilhuis, H, Goldstein, J, Goyal, N, Granit, V, Grapperon, A, Gutiérrez Gutiérrez, G, Gutmann, L, Hadden, R, Holbech, J, Holt, J, Homedes Pedret, C, Htut, M, Jellema, K, JericÃ3 Pascual, I, Kaida, K, Karafiath, S, Katzberg, H, Kiers, L, Kieseier, B, Kimpinski, K, Kleyweg, R, Kokubun, N, Kolb, N, Kuitwaard, K, Kuwabara, S, Kwan, J, Ladha, S, Landschoff Lassen, L, Lawson, V, Ledingham, D, Léon Cejas, L, Luciano, C, Lucy, S, Lunn, M, Magot, A, Manji, H, Marchesoni, C, Marfia, G, Márquez Infante, C, Martinez Hernandez, E, Mataluni, G, Mattiazi, M, Mcdermott, C, Meekins, G, Miller, J, Monges, M, Montero, M, Morís de la Tassa, G, Nascimbene, C, Neumann, C, Nowak, R, Orizaola Balaguer, P, Osei Bonsu, M, Pan, E, Pardo Fernandez, J, Pasnoor, M, Pulley, M, Rajabally, Y, Rinaldi, S, Ritter, C, Roberts, R, Rojas Marcos, I, Rudnicki, S, Sachs, G, Samijn, J, Santoro, L, Saperstein, D, Savransky, A, Schneider, H, Schenone, A, Sedano Tous, M, Sekiguchi, Y, Sheikh, K, Silvestri, N, Sindrup, S, Sommer, C, Stein, B, Stino, A, Spyropoulos, A, Srinivasan, J, Suzuki, H, Taylor, S, Tankisi, H, Tigner, D, Twydell, P, Valzania, F, van Damme, P, van der Kooi, A, van Dijk, G, van der Ree, T, van Koningsveld, R, Varrato, J, Vermeij, F, Verschuuren, J, Visser, L, Vytopil, M, Waheed, W, Wilken, M, Wilkerson, C, Wirtz, P, Yamagishi, Y, Yiu, E, Zhou, L, Zivkovic, S, Zivkovic, S., BINDA, DAVIDE, CAVALETTI, GUIDO ANGELO, Jacobs, B, van den Berg, B, Verboon, C, Chavada, G, Cornblath, D, Gorson, K, Harbo, T, Hartung, H, Hughes, R, Kusunoki, S, van Doorn, P, Willison, H, van Woerkom, M, Roodbol, J, Reisin, R, Reddel, S, Islam, Z, Islam, B, Mohammad, Q, van den Bergh, P, Feasby, T, Wang, Y, Pã©rã©on, Y, Lehmann, H, Dardiotis, E, Nobile Orazio, E, Shahrizaila, N, Bateman, K, Illa, I, Querol, L, Hsieh, S, Davidson, A, Addington, J, Ajroud Driss, S, Andersen, H, Antonini, G, Attarian, S, Badrising, U, Barroso, F, Benedetti, L, Beronio, A, Bianco, M, Binda, D, Briani, C, Bã1⁄4rmann, J, Bella, I, Bertorini, T, Bhavaraju Sanka, R, Brannagan, T, Busby, M, Butterworth, S, Campagnolo, M, Casasnovas, C, Cavaletti, G, Chao, C, Chen, S, Chetty, S, Claeys, K, Cohen, J, Conti, M, Cosgrove, J, Dalakas, M, Dimachkie, M, Dillmann, U, Domínguez González, C, Doppler, K, Dornonville de la Cour, C, Echaniz Laguna, A, Eftimov, F, Faber, C, Fazio, R, Fokke, C, Fujioka, T, Fulgenzi, E, Galassi, G, Garcia, T, Garnero, M, Garssen, M, Gijsbers, C, Gilchrist, J, Gilhuis, H, Goldstein, J, Goyal, N, Granit, V, Grapperon, A, Gutiérrez Gutiérrez, G, Gutmann, L, Hadden, R, Holbech, J, Holt, J, Homedes Pedret, C, Htut, M, Jellema, K, JericÃ3 Pascual, I, Kaida, K, Karafiath, S, Katzberg, H, Kiers, L, Kieseier, B, Kimpinski, K, Kleyweg, R, Kokubun, N, Kolb, N, Kuitwaard, K, Kuwabara, S, Kwan, J, Ladha, S, Landschoff Lassen, L, Lawson, V, Ledingham, D, Léon Cejas, L, Luciano, C, Lucy, S, Lunn, M, Magot, A, Manji, H, Marchesoni, C, Marfia, G, Márquez Infante, C, Martinez Hernandez, E, Mataluni, G, Mattiazi, M, Mcdermott, C, Meekins, G, Miller, J, Monges, M, Montero, M, Morís de la Tassa, G, Nascimbene, C, Neumann, C, Nowak, R, Orizaola Balaguer, P, Osei Bonsu, M, Pan, E, Pardo Fernandez, J, Pasnoor, M, Pulley, M, Rajabally, Y, Rinaldi, S, Ritter, C, Roberts, R, Rojas Marcos, I, Rudnicki, S, Sachs, G, Samijn, J, Santoro, L, Saperstein, D, Savransky, A, Schneider, H, Schenone, A, Sedano Tous, M, Sekiguchi, Y, Sheikh, K, Silvestri, N, Sindrup, S, Sommer, C, Stein, B, Stino, A, Spyropoulos, A, Srinivasan, J, Suzuki, H, Taylor, S, Tankisi, H, Tigner, D, Twydell, P, Valzania, F, van Damme, P, van der Kooi, A, van Dijk, G, van der Ree, T, van Koningsveld, R, Varrato, J, Vermeij, F, Verschuuren, J, Visser, L, Vytopil, M, Waheed, W, Wilken, M, Wilkerson, C, Wirtz, P, Yamagishi, Y, Yiu, E, Zhou, L, Zivkovic, S, Zivkovic, S., BINDA, DAVIDE, and CAVALETTI, GUIDO ANGELO

Abstract

Guillain-Barré syndrome (GBS) is an acute polyradiculoneuropathy with a highly variable clinical presentation, course, and outcome. The factors that determine the clinical variation of GBS are poorly understood which complicates the care and treatment of individual patients. The protocol of the ongoing International GBS Outcome Study (IGOS), a prospective, observational, multicenter cohort study that aims to identify the clinical and biological determinants and predictors of disease onset, subtype, course and outcome of GBS is presented here. Patients fulfilling the diagnostic criteria for GBS, regardless of age, disease severity, variant forms, or treatment, can participate if included within 2 weeks after onset of weakness. Information about demography, preceding infections, clinical features, diagnostic findings, treatment, course, and outcome is collected. In addition, cerebrospinal fluid and serial blood samples for serum and DNA is collected at standard time points. The original aim was to include at least 1,000 patients with a follow-up of 1–3 years. Data are collected via a web-based data entry system and stored anonymously. IGOS started in May 2012 and by January 2017 included more than 1,400 participants from 143 active centers in 19 countries across 5 continents. The IGOS data/biobank is available for research projects conducted by expertise groups focusing on specific topics including epidemiology, diagnostic criteria, clinimetrics, electrophysiology, antecedent events, antibodies, genetics, prognostic modeling, treatment effects, and long-term outcome of GBS. The IGOS will help to standardize the international collection of data and biosamples for future research of GBS.

Published
2017

33. Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20)

Author

Kieffer, J. M., Postma, T. J., van de Poll-Franse, L., Mols, F., Heimans, J. J., Cavaletti, G., Aaronson, N. K., Cornblath, D. R., Merkies, I. S. J., Valsecchi, M. G., Galimberti, S., Rossi, E., Frigeni, B., Lanzani, F., Mattavelli, L., Piatti, M. L., Alberti, P., Binda, D., Bidoli, P., Cazzaniga, M., Cortinovis, D., Bruna, J., Velasco, R., Argyriou, A. A., Kalofonos, H. P., Psimaras, D., Ricard, D., Pace, A., Galie, E., Briani, C., Lucchetta, M., Campagnolo, M., Torre, C. D., Faber, C. G., Vanhoutte, E. K., Bakkers, M., Brouwer, B., Boogerd, M., Lalisang, R. I., Boogerd, W., Brandsma, D., Koeppen, S., Hense, J., Grant, R., Storey, D., Kerrigan, S., Schenone, A., Reni, L., Piras, B., Fabbri, S., Pessino, A., Padua, L., Granata, G., Leandri, M., Ghignotti, I., Plasmati, R., Pastorelli, F., Eurelings, M., Meijer, R. J., Grisold, W., Pozza, E. L., Mazzeo, A., Toscano, A., Russo, M., Tomasello, C., Altavilla, G., Prado, M. P., Gonzalez, C. D., Dorsey, S. G., Padua L. (ORCID:0000-0003-2570-9326), Kieffer, J. M., Postma, T. J., van de Poll-Franse, L., Mols, F., Heimans, J. J., Cavaletti, G., Aaronson, N. K., Cornblath, D. R., Merkies, I. S. J., Valsecchi, M. G., Galimberti, S., Rossi, E., Frigeni, B., Lanzani, F., Mattavelli, L., Piatti, M. L., Alberti, P., Binda, D., Bidoli, P., Cazzaniga, M., Cortinovis, D., Bruna, J., Velasco, R., Argyriou, A. A., Kalofonos, H. P., Psimaras, D., Ricard, D., Pace, A., Galie, E., Briani, C., Lucchetta, M., Campagnolo, M., Torre, C. D., Faber, C. G., Vanhoutte, E. K., Bakkers, M., Brouwer, B., Boogerd, M., Lalisang, R. I., Boogerd, W., Brandsma, D., Koeppen, S., Hense, J., Grant, R., Storey, D., Kerrigan, S., Schenone, A., Reni, L., Piras, B., Fabbri, S., Pessino, A., Padua, L., Granata, G., Leandri, M., Ghignotti, I., Plasmati, R., Pastorelli, F., Eurelings, M., Meijer, R. J., Grisold, W., Pozza, E. L., Mazzeo, A., Toscano, A., Russo, M., Tomasello, C., Altavilla, G., Prado, M. P., Gonzalez, C. D., Dorsey, S. G., and Padua L. (ORCID:0000-0003-2570-9326)

Abstract

Purpose: To investigate the scale structure and psychometrics of the EORTC chemotherapy-induced peripheral neuropathy module (QLQ-CIPN20). Methods: Using confirmatory factor analyses (CFA), we tested two hypothesized scale structure models of the QLQ-CIPN20 in 473 patients with non-small cell lung cancer, 281 patients with heterogeneous cancer diagnoses, and 500 patients with colorectal cancer. We also modeled the two hypothesized models as bi-factor models. These included a general factor, in addition to the specific domain factors. Additional models were investigated with exploratory factor analysis (EFA). Known groups validity was evaluated where justified. Results: CFA could not confirm the two hypothesized models (Model 1: CFI < 0.926; TLI < 0.914; RMSEA > 0.077 and Model 2: CFI < 0.906; TLI < 0.887; RMSEA > 0.105) in any of the three samples. Including a general factor to these two hypothesized models to produce a bi-factor model also did not yield satisfactory results. Using EFA, we identified four different factor structures in the three samples that were unstable due to cross loadings of the items. When scoring the QLQ-CIPN20 as a simple, additive checklist evidence was found for known groups validity in the first two samples based on Common Toxicity Criteria (CTC-AE), and in the third sample based on exposure to CIPN-inducing chemotherapy. Conclusions: Neither CFA nor EFA yielded support for a stable subscale structure for the QLQ-CIPN20. Scoring the questionnaire as a simple additive checklist results in acceptable validity.

Published
2017

34. The significance of dorsal sural nerve recordings in early detecting oxaliplatin-induced peripheral neuropathy

Author

Paola Alberti, Cacciavillani, M., Bruna, J., Velasco, R., Briani, C., Campagnolo, M., Roncaletti, S., Cazzaniga, M., Cortinovis, D., Kalofonos, H. P., Cavaletti, G., Argyriou, A. A., Alberti, P, Cacciavillani, M, Bruna, J, Roser, V, Briani, C, Campagnolo, M, Roncaletti, S, Cazzaniga, M, Cortinovis, D, Kalofonos, H, Cavaletti, G, and Argyriou, A

Subjects
Peripheral Neurotoxicity, Dorsal Sural Nerve, Outcome Measures
Abstract

INTRODUCTION: Thus far, there is no gold standard for the accurate monitoring of Oxaliplatin-induced peripheral neuropathy (OXAIPN). For anatomical reasons, Dorsal Sural Nerve (DSN) conduction study might be able to predict the neurological outcome at end of chemotherapy. Our objective was to assess its ability to early detect OXAIPN. METHODS: A total of 116 colorectal cancer patients [75 (64,6%) male, 41 (35,4%) female, median age of 64 years; range: 38-77 y.o.] were evaluated before, at middle-point and at the end of chemotherapy. Standard nerve conduction studies plus DSN were performed. The Total Neuropathy Score–clinical version (TNSc) was used to assess OXAIPN. Elaborating a tree regression, cut-offs for z-score of DSN amplitude were individuated to subdivide at mid-treatment subjects at high versus low risk to develop neurotoxicity at the end of chemotherapy. RESULTS: At baseline all patients had no preexisting neuropathy. At mid-treatment, 11 (9,5%) patients had abnormal sural nerve amplitudes and 24 (20,7%) abnormal DSN amplitudes. At the end of treatment, 37 (32%) patients had grade I neuropathy and 37 (32%) had grade II/III. Forty-four (38%) patients had abnormal sural nerve amplitudes and 55 (47,4%) had abnormal DSN amplitudes. The -0.815 cut-off for the z-score of DSN amplitude was able to individuate the probability of patients to develop OXAIPN, better than sensory nerves conventionally studied, e.g., sural nerve. CONCLUSIONS: DSN recording might be a useful objective outcome measure to individuate patients at higher risk to develop neurotoxicity during chemotherapy. It might also be a significant end-point in neuroprotection trials.

Published
2014

35. Rasch-Transformed Total Neuropathy Score clinical version (RT-TNSc©) in patients with chemotherapy-induced peripheral neuropathy

Author

Binda, D, Cavaletti, G, Cornblath, Dr, Merkies, Is, CI PeriNomS, Sg, Postma, Tj, Valsecchi, Mg, Galimberti, S, Rossi, E, Frigeni, B, Lanzani, F, Mattavelli, L, Piatti, Ml, Alberti, P, Bidoli, P, Cazzaniga, M, Cortinovis, D, Bruna, J, Velasco, R, Argyriou, Aa, Kalofonos, Hp, Psimaras, D, Ricard, D, Pace, A, Galiè, E, Briani, C, Lucchetta, M, Campagnolo, M, Dalla Torre, C, Faber, Cg, Vanhoutte, Ek, Bakkers, M, Brouwer, B, Boogerd, M, Lalisang, Ri, Boogerd, W, Brandsma, D, Koeppen, S, Grant, R, Storey, D, Kerrigan, S, Schenone, Angelo, Reni, L, Piras, B, Fabbri, S, Pessino, A, Padua, L, Granata, G, Leandri, M, Ghignotti, I, Plasmati, R, Pastorelli, F, Heimans, Jj, Eurelings, M, Meijer, Rj, Josef, Kf, Grisold, W, Lindeck Pozza, E, Mazzeo, A, Toscano, A, Russo, M, Tomasello, C, Altavilla, G, Penas Prado, M, Dominguez Gonzalez, C, Dorsey, S. g., RS: GROW - Oncology, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Binda, D, Cavaletti, G, Cornblath, D, Merkies, I, Valsecchi, M, and Bidoli, P

Subjects
Rasch analysi, Male, psychometrics, medicine.medical_specialty, peripheral neuropathy, Drug-Related Side Effects and Adverse Reactions, Psychometrics, psychometric, chemotherapy, Rasch analysis, total neuropathy score, Neurology (clinical), Neuroscience (all), Severity of Illness Index, Age Factors, Female, Humans, Peripheral Nervous System Diseases, Quality of Life, Retrospective Studies, Disability Evaluation, Medicine (all), Physical medicine and rehabilitation, Quality of life, Severity of illness, Medicine, Balance (ability), Rasch model, business.industry, General Neuroscience, Retrospective cohort study, medicine.disease, Peripheral neuropathy, Chemotherapy-induced peripheral neuropathy, Physical therapy, business
Abstract

Composite scales such as the Total Neuropathy Score clinical version (TNSc(©) ) have been widely used to measure neurological impairment in a standardized manner but they have been criticized due to their ordinal setting having no fixed unit. This study aims to improve impairment assessment in patients with chemotherapy-induced peripheral neuropathy (CIPN) by subjecting TNSc(©) records to Rasch analyses. In particular, we wanted to investigate the influence of factors affecting the use of the TNSc(©) in clinical practice. TNSc(©) has 7 domains (sensory, motor, autonomic, pin-prick, vibration, strength, and deep tendon reflexes [DTR]) each being scored 0-4. Data obtained in 281 patients with stable CIPN were subjected to Rasch analyses to determine the fit to the model. The TNSc(©) did not meet Rasch model's expectations primarily because of misfit statistics in autonomic and DTR domains. Removing these two, acceptable model fit and uni-dimensionality were obtained. However, disordered thresholds (vibration and strength) and item bias (mainly cultural) were still seen, but these findings were kept to balance the assessment range of the Rasch-Transformed TNSc(©) (RT-TNSc(©) ). Acceptable reliability findings were also obtained. A 5-domains RT-TNSc(©) may be a more proper assessment tool in patients with CIPN. Future studies are needed to examine its responsive properties.

Published
2015

37. Nerve ultrasound findings in neuropathy associated with anti-myelin-associated glycoprotein antibodies

Author

Lucchetta, M, Padua, Luca, Granata, Giuseppe, Luigetti, Marco, Campagnolo, M, Dalla Torre, C, Coraci, D, Sabatelli, Mario, Briani, C., Padua, Luca (ORCID:0000-0003-2570-9326), Luigetti, Marco (ORCID:0000-0001-7539-505X), Sabatelli, Mario (ORCID:0000-0001-6635-4985), Lucchetta, M, Padua, Luca, Granata, Giuseppe, Luigetti, Marco, Campagnolo, M, Dalla Torre, C, Coraci, D, Sabatelli, Mario, Briani, C., Padua, Luca (ORCID:0000-0003-2570-9326), Luigetti, Marco (ORCID:0000-0001-7539-505X), and Sabatelli, Mario (ORCID:0000-0001-6635-4985)

Abstract

No systematic nerve ultrasound (US) studies on patients with neuropathy and anti-myelin-associated glycoprotein (anti-MAG) antibodies are available.

Published
2015

38. Following up the long-term Course of Oxaliplatin-Induced Peripheral Neurotoxicity

Author

Alberti, P, Izquierdo, C, Campagnolo, M, Velasco, R, Caccavillani, M, Bruna, J, Cavaletti, G, Briani, C, Argyriou, A, ALBERTI, PAOLA, CAVALETTI, GUIDO ANGELO, Argyriou, A., Alberti, P, Izquierdo, C, Campagnolo, M, Velasco, R, Caccavillani, M, Bruna, J, Cavaletti, G, Briani, C, Argyriou, A, ALBERTI, PAOLA, CAVALETTI, GUIDO ANGELO, and Argyriou, A.

Published
2015

39. Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: A genome-wide study replication and meta-analysis

Author

Terrazzino, S, Argyriou, A, Cargnin, S, Antonacopoulou, A, Briani, C, Bruna, J, Velasco, R, Alberti, P, Campagnolo, M, Lonardi, S, Cortinovis, D, Cazzaniga, M, Santos, C, Kalofonos, H, Canonico, P, Genazzani, A, Cavaletti, G, ALBERTI, PAOLA, CORTINOVIS, DIEGO LUIGI, CAZZANIGA, MARINA ELENA, CAVALETTI, GUIDO ANGELO, Terrazzino, S, Argyriou, A, Cargnin, S, Antonacopoulou, A, Briani, C, Bruna, J, Velasco, R, Alberti, P, Campagnolo, M, Lonardi, S, Cortinovis, D, Cazzaniga, M, Santos, C, Kalofonos, H, Canonico, P, Genazzani, A, Cavaletti, G, ALBERTI, PAOLA, CORTINOVIS, DIEGO LUIGI, CAZZANIGA, MARINA ELENA, and CAVALETTI, GUIDO ANGELO

Abstract

We aimed at validating the role of genetic variants identified by a recent genome-wide association study (GWAS) as determinants of chronic oxaliplatin-induced peripheral neurotoxicity (OXAIPN). Eight polymorphisms (rs10486003, rs2338, rs843748, rs797519, rs4936453, rs12023000, rs17140129, and rs6924717) were genotyped in a total of 150 colorectal cancer patients of Caucasian origin receiving oxaliplatin-based chemotherapy. The severity grade of chronic OXAIPN was assessed by NCI-CTC criteria and the clinical version of the Total Neuropathy Score© (TNSc©). None of the polymorphisms investigated was found associated with grade ≥ chronic OXAIPN (NCI-CTC criteria), while a nominal association emerged for ACYP2 rs843748 when using the TNSc© scale (dominant model: odds ratio [OR]: 0.27, 95% confidence interval [CI]: 0.10-0.75, P=0.008). In the combined analysis of this results with data of the two previously published studies which assessed chronic OXAIPN by NCI-CTC criteria, evidence suggestive of association with chronic OXAIPN (NCI-CTC criteria) was found for ACYP2 rs843748 (dominant model: OR: 2.40, 95%CI: 1.40-5.24, P=0.027), which, however, did not remain significant after correction for multiple testing (threshold P-value <0.00625). These findings suggest a minor role of the single nucleotide polymorphisms (SNPs) investigated as genetic determinants of chronic OXAIPN. These results also highlight the importance of replication studies with meta-analysis for validation of GWAS findings.

Published
2015

40. Long-term plasma exchange in pediatric CIDP

Author

Lucchetta, M., Vidal, E., Sartori, S., Campagnolo, M., Torre, C. D., Marson, P., Manara, R., and Briani, C.

Subjects
Male, Time Factors, Treatment Outcome, Adolescent, Plasma Exchange, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Glomerulonephritis, Membranoproliferative, Renal Dialysis, Humans, Kidney Failure, Chronic
Abstract

Therapeutic plasma exchange (TPE) is not frequently used in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) because it usually gives only a short-term benefit. We report on a 16-year-old boy with renal insufficiency undergoing hemodialysis who developed CIDP and underwent TPE with dramatic long-term response to therapy. Nerve ultrasound and MRI findings are also reported. In our patient TPE was chosen because he was already undergoing hemodialysis. Though it is not considered a first-line therapy in pediatric CIDP, TPE may be a good therapeutic choice also in long-term period.

Published
2013

44. Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy. A nationwide retrospective analysis

Author

Cocito, D, Grimaldi, S, Paolasso, I, Falcone, Y, Antonini, G, Benedetti, L, Briani, C, Fazio, R, Jann, S, Mata, S, Sabatelli, M, Nobile-Orazio, E, Italian Network for CIDP Register, Ciaramitano, P, Cossa, Fm, Clemenzi, A, Garibaldi, M, Beronio, A, Schenone, A, Campagnolo, M, Dalla Torre, C, Fruguglietti, E, Borsini, W, Conte, A, Luigetti, M, Gallia, F, and Terenghi, F

Subjects
Adult, Male, Adolescent, Drug Resistance, Severity of Illness Index, Antibodies, Monoclonal, Murine-Derived, Young Adult, chronic inflammatory demyelinating polyneuropathy, Azathioprine, immunosuppressant drugs, Humans, Immunologic Factors, Child, Cyclophosphamide, Aged, Retrospective Studies, chronic inflammatory demyelinating polyradiculoneuropathy, therapy, Remission Induction, Immunoglobulins, Intravenous, Interferon-alpha, Interferon-beta, Plasmapheresis, Middle Aged, Mycophenolic Acid, Axons, Methotrexate, Treatment Outcome, Italy, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Cyclosporine, Female, Rituximab, Immunosuppressive Agents, Interferon beta-1a
Abstract

There are other options open to patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) who are non-responders to conventional treatment, including immunosuppressive and immunomodulatory agents (IA). The aim of this study was to assess whether the use of IA is able to increase the number of responders.Clinical and electrophysiological data of patients with refractory CIDP, followed at 10 Italian centres, were collected, and the clinical outcome (Rankin Scale) and drug side effects (SE) for the different therapies were analysed.A total of 110 patients were included. These patients underwent 158 different therapeutic procedures with IA. Seventy-seven patients were treated with azathioprine, 18 rituximab, 13 cyclophosphamide, 12 mycophenolate mofetil, 12 cyclosporine, 12 methotrexate, 11 interferon-alpha and three interferon beta-1a. The percentage of patients who responded to azathioprine (27%) was comparable to the percentage of responders to other therapies, after the exclusion of interferon beta-1a that was not effective in any of the three patients treated. The percentage of SE ranges from 8% (methotrexate) to 50% (cyclosporine).One-fourth of patients, refractory to conventional treatment, showed an improvement in their disability with IA. Methotrexate had the lowest SE; cyclosporine was associated with severe SE and often led to drug discontinuation.

Published
2011

47. Vascular endothelial growth factor helps differentiate neuropathies in rare plasma cell dyscrasias

Author

Briani, Chiara, Fabrizi, Gm, Ruggero, S, Torre, Cd, Ferrarini, M, Campagnolo, M, Cavallaro, T, Ferrari, S, Scarlato, M, Taioli, F, and Adami, Fausto

Subjects
Adult, Male, Vascular Endothelial Growth Factor A, POEMS Syndrome, Paraproteinemias, Humans, Female, Middle Aged, Statistics, Nonparametric, Aged
Abstract

POEMS syndrome and amyloidosis are rare plasma cell diseases that share common features, including polyneuropathy. The aim of this study was to investigate serum vascular endothelial growth factor (sVEGF) in patients with amyloidosis and to evaluate changes in response to treatment. Twenty-five patients [17 primary light-chain amyloidosis (AL-A), 7 transthyretin amyloidosis (TTR-A), 1 senile wild-type TTR-A] were studied. sVEGF was analyzed by ELISA. Sera from 8 myeloma and 7 POEMS patients were also evaluated. The median sVEGF level was 420 pg/ml in AL-A and 179 pg/ml in TTR-A patients; this was significantly lower than in POEMS syndrome (median 2580 pg/ml, P = 0.0002 and 0.001, respectively). sVEGF of AL-A patients showed no changes in response to treatment. sVEGF was not increased in amyloid patients regardless of neuropathy, and did not mirror the course of the disease. sVEGF should be tested in patients with overlapping and atypical clinical features.

Published
2010

50. A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy

Author

Cocito, D, Paolasso, I, Antonini, G, Benedetti, L, Briani, C, Comi, C, Fazio, R, Jann, S, Mata, S, Mazzeo, S, Sabatelli, M, Nobile-Orazio, E, Behalf Of The Italian Network For Cidp Register, O. N., Grimaldi, S, Falcone, Y, Ciaramitaro, P, Cossa, Fm, Clemenzi, A, Garibaldi, M, Beronio, A, Schenone, A, Campagnolo, M, Dalla Torre, C, Fruguglietti, Me, Borsini, W, Conte, A, Luigetti, M, Gallia, F, and Terenghi, F

Subjects
chronic inflammatory demyelinating polyneuropathy, corticosteroids, immunoglobulins, immunosuppressant drugs, plasma exchange, therapy
Published
2010

Catalog

Books, media, physical & digital resources
See catalog results